John Howard Sampson
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine
Current research activities involve the immunotherapeutic targeting of a tumor-specific mutation in the epidermal growth factor receptor. Approaches used to target this tumor-specific epitope include unarmed and radiolabeled antibody therapy and cell mediated approaches using peptide vaccines and dendritic cells. Another area of interest involves drug delivery to brain tumors. Translational and clinical work is carried out in this area to formulate the relationship between various direct intratumoral infusion parameters and drug distribution within brain tumors and normal brain.
The Duke Brain Tumor Immunotherapy Program (BTIP) has an emphasis on translational research in Neuro-Oncology. There are two main areas of study. The first is novel mechanisms of delivery of large molecular weight molecules, such as monoclonal antibodies, throughout brain intersitial space using novel intracerebral infusion techniques developed by this laboratory. Studies exploring this technology are undertaken in both small and large laboratory animals and patients with brain tumors.
The other focus of the BTIP is translational immunotherapy. In this line of work, dendritic cell vaccination strategies and adoptive T-cell strategies have been developed to target novel and well-characterized tumor-specific antigens in patients with brain tumors. The BTIP integrates well with and works closely with the Preston Robert Tisch Brain Tumor Center at Duke. The BTIP is well funded and currently holds seven NIH grants, including a SPORE in Brain Cancer grant. There are a large number of investigators at various levels so that students will get exposure to various levels of research and mentorship.
The Duke Brain Tumor Immunotherapy Program (BTIP) has an emphasis on translational research in Neuro-Oncology. There are two main areas of study. The first is novel mechanisms of delivery of large molecular weight molecules, such as monoclonal antibodies, throughout brain intersitial space using novel intracerebral infusion techniques developed by this laboratory. Studies exploring this technology are undertaken in both small and large laboratory animals and patients with brain tumors.
The other focus of the BTIP is translational immunotherapy. In this line of work, dendritic cell vaccination strategies and adoptive T-cell strategies have been developed to target novel and well-characterized tumor-specific antigens in patients with brain tumors. The BTIP integrates well with and works closely with the Preston Robert Tisch Brain Tumor Center at Duke. The BTIP is well funded and currently holds seven NIH grants, including a SPORE in Brain Cancer grant. There are a large number of investigators at various levels so that students will get exposure to various levels of research and mentorship.
Current Appointments & Affiliations
- Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Neurosurgery, Neurosurgery 2009
- Professor of Neurosurgery, Neurosurgery, Neurosurgery 2009
- Professor of Integrative Immunobiology, Integrative Immunobiology, Basic Science Departments 2009
- Professor of Radiation Oncology, Radiation Oncology, Clinical Science Departments 2009
- Professor of Pathology, Pathology, Clinical Science Departments 2012
- Professor of Biomedical Engineering, Biomedical Engineering, Pratt School of Engineering 2013
- Professor in Orthopaedic Surgery, Orthopaedic Surgery, Clinical Science Departments 2017
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1990
Contact Information
- 1293 Orange Zone, Duke South, 200 Trent Dr, Durham, NC 27710
- Box 3810 Med Ctr, Durham, NC 27710
-
john.sampson@duke.edu
(919) 681-6581
- Background
-
Education, Training, & Certifications
- M.B.A., Duke University 2011
- M.H.S., Duke University School of Medicine 2007
- Resident in Neurosurgery, Surgery, Duke University 1991 - 1998
- Ph.D., Duke University 1996
- Intern, Surgery, Duke University 1990 - 1991
- M.D., University of Manitoba (Canada) 1990
- Investigator in Cerebral Hydrodynamics Lab, Neurosurgery, University of Manitoba (Canada) 1987 - 1989
-
Previous Appointments & Affiliations
- Chair, Department of Neurosurgery, Neurosurgery, Clinical Science Departments 2015 - 2020
- Interim Cheif of the Division of Neurosurgery, Neurosurgery, Neurosurgery 2014 - 2015
- Professor of Pathology, Pathology, Clinical Science Departments 2009 - 2010
- Associate Professor of Pathology, Pathology, Clinical Science Departments 2008 - 2009
- Associate Professor of Surgery, Neurosurgery, Neurosurgery 2008 - 2009
- Associate Professor of Radiation Oncology, Radiation Oncology, Clinical Science Departments 2009
- Associate Professor of Immunology, Integrative Immunobiology, Basic Science Departments 2009
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 1999 - 2008
- Associate Professor of Surgery, Neurosurgery, Neurosurgery 2003 - 2008
- Assistant Professor of Surgery, Neurosurgery, Neurosurgery 1998 - 2003
- Instructor, Temporary of Surgery, Neurosurgery, Neurosurgery 1998
- Recognition
-
In the News
-
NOV 4, 2022 Duke Health News -
MAR 9, 2020 Duke Health News -
OCT 16, 2017 Duke Health News -
JUL 5, 2017 Clinical Practice Today -
APR 16, 2017 Duke Health News -
MAY 25, 2016 -
FEB 10, 2016 -
DEC 16, 2015 NBC Nightly News -
JUL 16, 2015 -
JUN 2, 2015 CBS News -
APR 14, 2015 Clinical Practice Today -
MAR 30, 2015 CBS “60 Minutes -
MAR 12, 2015 “NBC Nightly News” -
MAR 12, 2015 "CBS Evening News” -
MAR 12, 2015 -
MAR 11, 2015 The Wall Street Journal
-
-
Awards & Honors
- Expertise
-
Subject Headings
- 3T3 Cells
- Abortion
- Academic Medical Centers
- Adipates
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Alcohol Oxidoreductases
- Amino Acid Sequence
- Angiogenesis Inhibitors
- Antibiotics, Antineoplastic
- Antibodies
- Antibodies, Bispecific
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm
- Antibody Affinity
- Antibody Formation
- Antibody Specificity
- Anticonvulsants
- Antigen Presentation
- Antigen-Antibody Complex
- Antigen-Presenting Cells
- Antigens
- Antigens, CD3
- Antigens, CD4
- Antigens, Differentiation
- Antigens, Neoplasm
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Antineoplastic Agents, Phytogenic
- Antineoplastic Combined Chemotherapy Protocols
- Antitubercular Agents
- Astrocytoma
- Ataxia
- Benzamides
- Benzenesulfonates
- Biological Assay
- Biopsy
- Bispecific antibodies
- Blood-Brain Barrier
- Blotting, Western
- Body Burden
- Body Mass Index
- Bone Marrow Cells
- Brain
- Brain Diseases
- Brain Neoplasms
- Breast Neoplasms
- CD4-Positive T-Lymphocytes
- CD8-Positive T-Lymphocytes
- CHO Cells
- Camptothecin
- Cancer Vaccines
- Carboplatin
- Carcinogenicity Tests
- Carmustine
- Catalytic Domain
- Catheterization
- Catheters, Indwelling
- Cell Culture Techniques
- Cell Division
- Cell Line
- Cell Line, Tumor
- Cell Membrane
- Cell Movement
- Cell Proliferation
- Cell Survival
- Cells, Cultured
- Central Nervous System
- Central Nervous System Neoplasms
- Cerebral Cortex
- Cerebrospinal Fluid Shunts
- Cerebrovascular Disorders
- Cervical Vertebrae
- Chemokines
- Chemoradiotherapy
- Chemotherapy
- Chemotherapy, Adjuvant
- Chi-Square Distribution
- Child
- Child, Preschool
- Chimera
- Cholesterol
- Chromatography
- Cisplatin
- Clinical Trials as Topic
- Clinical Trials, Phase III as Topic
- Cluster Analysis
- Coculture Techniques
- Cognition
- Cohort Studies
- Combined Modality Therapy
- Complementarity Determining Regions
- Cone-Beam Computed Tomography
- Confidence Intervals
- Contrast Media
- Convection
- Cranial Irradiation
- Cranial Nerve Diseases
- Cranial Nerve Neoplasms
- Craniocerebral Trauma
- Craniotomy
- Culture Media, Conditioned
- Cytochrome P-450 CYP3A
- Cytokines
- Cytotoxicity Tests, Immunologic
- Cytotoxicity, Immunologic
- DNA Methylation
- DNA Modification Methylases
- DNA Mutational Analysis
- DNA Repair Enzymes
- DNA Topoisomerases, Type I
- Dacarbazine
- Dactinomycin
- Data Collection
- Decanoic Acids
- Decompression, Surgical
- Dendritic Cells
- Diagnosis, Differential
- Diagnostic Imaging
- Disease Models, Animal
- Disease Progression
- Disease-Free Survival
- Dose Fractionation
- Dose-Response Relationship, Drug
- Dose-Response Relationship, Radiation
- Drug Administration Routes
- Drug Administration Schedule
- Drug Delivery Systems
- Drug Evaluation, Preclinical
- Drug Implants
- Drug Resistance, Neoplasm
- Drug Screening Assays, Antitumor
- Drug Synergism
- Drug Therapy, Combination
- Drugs, Chinese Herbal
- Ear Neoplasms
- Education, Graduate
- Electrocoagulation
- Electrophoresis, Gel, Two-Dimensional
- Electrophoresis, Polyacrylamide Gel
- Electroporation
- Encephalomyelitis, Autoimmune, Experimental
- Enzyme Inhibitors
- Enzyme-Linked Immunosorbent Assay
- Eosinophilic Granuloma
- Epidermal Growth Factor
- Epitopes
- Equipment Design
- Escherichia coli
- Etoposide
- Exophthalmos
- Exosomes
- Exotoxins
- Facial Nerve
- Female
- Flow Cytometry
- Follow-Up Studies
- Forkhead Transcription Factors
- Gadolinium DTPA
- Gene Expression
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Gene Transfer Techniques
- Genetic Engineering
- Genetic Techniques
- Genetic Testing
- Genetic Therapy
- Genetic Vectors
- Genotype
- Glasgow Coma Scale
- Glioblastoma
- Glioma
- Glossopharyngeal Nerve Diseases
- Goals
- Guanine
- HIV Infections
- Head
- Head and Neck Neoplasms
- Health Care Costs
- Health Services Accessibility
- Hemocyanin
- Histocompatibility Antigens Class I
- History, 20th Century
- History, 21st Century
- Homeless Persons
- Homosexuality
- Humans
- Hydroxyurea
- Hypersensitivity, Delayed
- Image Processing, Computer-Assisted
- Imaging
- Immune System
- Immunity
- Immunity, Innate
- Immunization
- Immunocompetence
- Immunocompromised Host
- Immunoenzyme Techniques
- Immunoglobulin G
- Immunoglobulin Idiotypes
- Immunohistochemistry
- Immunologic Surveillance
- Immunomodulation
- Immunosuppression
- Immunosuppressive Agents
- Immunotherapy
- Immunotherapy, Adoptive
- Immunotoxins
- Indicators and Reagents
- Individualized Medicine
- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Infant
- Infratentorial Neoplasms
- Infusion Pumps
- Infusion Pumps, Implantable
- Infusions, Intra-Arterial
- Infusions, Intravenous
- Injections, Intradermal
- Injections, Intralesional
- Injections, Intravenous
- Injections, Intraventricular
- Injury Severity Score
- Interferon-gamma
- Interleukin-13
- Interleukin-2
- Interleukin-2 Receptor alpha Subunit
- Intraocular Pressure
- Intraoperative Complications
- Iodine Radioisotopes
- Isocitrate Dehydrogenase
- Isotope Labeling
- Kaplan-Meier Estimate
- Keratinocytes
- Language
- Linear Models
- Liposomes
- Lung Neoplasms
- Lymph Nodes
- Lymphocyte Activation
- Lymphocyte Depletion
- Lymphocytes
- Lymphopenia
- Macrophages
- Magnetic Resonance Imaging
- Male
- Maximum Tolerated Dose
- Melanoma
- Melanoma, Experimental
- Membrane Proteins
- Meningeal Neoplasms
- Meningioma
- Meningitis
- Methods
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Inbred Strains
- Mice, Nude
- Mice, Transgenic
- Microcirculation
- Microinjections
- Microsurgery
- Middle Aged
- Models, Animal
- Models, Molecular
- Molecular Sequence Data
- Molecular Targeted Therapy
- Monitoring, Intraoperative
- Monocytes
- Movement
- Multivariate Analysis
- Mutagenesis, Site-Directed
- Mutant Proteins
- Mutation
- Naphthoquinones
- Neoplasm Grading
- Neoplasm Invasiveness
- Neoplasm Metastasis
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Neoplasm Transplantation
- Neoplasm, Residual
- Neoplasms
- Neoplasms, Experimental
- Neoplastic Stem Cells
- Neovascularization, Pathologic
- Nerve Compression Syndromes
- Nervous System Autoimmune Disease, Experimental
- Neural Stem Cells
- Neuroma, Acoustic
- Neurosurgical Procedures
- Niacinamide
- Nitrosourea Compounds
- North Carolina
- O(6)-Methylguanine-DNA Methyltransferase
- Observer Variation
- Oligodendroglioma
- Oligonucleotide Array Sequence Analysis
- Oncology
- Oncolytic Virotherapy
- Oncolytic Viruses
- Opportunistic Infections
- Pain Management
- Pain Measurement
- Palliative Care
- Paraganglioma
- Paranasal Sinus Diseases
- Paresis
- Patient Selection
- Peptide Fragments
- Peptides
- Phenylurea Compounds
- Phosphoproteins
- Phosphorylation
- Phytotherapy
- Pilot Projects
- Piperazines
- Plant Extracts
- Plants, Medicinal
- Poliomyelitis
- Polyesters
- Positron-Emission Tomography
- Postoperative Complications
- Posture
- Poverty
- Predictive Value of Tests
- Preoperative Care
- Prevalence
- Principal Component Analysis
- Prognosis
- Proportional Hazards Models
- Prospective Studies
- Protein Engineering
- Protein Kinase Inhibitors
- Protein Precursors
- Protein-Serine-Threonine Kinases
- Protein-Tyrosine Kinases
- Proteome
- Proteomics
- Proto-Oncogene Proteins
- Proto-Oncogene Proteins c-akt
- Publishing
- Pyridines
- Pyrimidines
- Quality of Life
- Quinazolines
- RNA Viruses
- Radiation Injuries
- Radiation Tolerance
- Radioimmunotherapy
- Radioligand Assay
- Radiometry
- Radiopharmaceuticals
- Radiosurgery
- Radiotherapy
- Radiotherapy Dosage
- Radiotherapy Planning, Computer-Assisted
- Radiotherapy, Adjuvant
- Radiotherapy, High-Energy
- Radiotherapy, Image-Guided
- Radiotherapy, Intensity-Modulated
- Randomized Controlled Trials as Topic
- Receptor, Epidermal Growth Factor
- Receptor, erbB-2
- Receptors, Antigen, T-Cell
- Receptors, Vascular Endothelial Growth Factor
- Recombinant Fusion Proteins
- Recombinant Proteins
- Recombination, Genetic
- Recurrence
- Registries
- Relative Biological Effectiveness
- Remission Induction
- Reoperation
- Reproducibility of Results
- Retinal Diseases
- Retrospective Studies
- Retroviridae
- Retroviridae Infections
- Risk Assessment
- Risk Factors
- Saccharomyces cerevisiae
- Safety
- Salvage Therapy
- Sample Size
- Saponins
- Sensitivity and Specificity
- Sequence Alignment
- Serum Albumin, Radio-Iodinated
- Signal Transduction
- Single-Chain Antibodies
- Sirolimus
- Skin Neoplasms
- Social Class
- Socioeconomic Factors
- Software
- Solubility
- Spinal Cord
- Spinal Cord Injuries
- Spinal Fusion
- Spinal Neoplasms
- Spleen
- Standard of Care
- Stereotaxic Techniques
- Steroids
- Subcutaneous Fat
- Substrate Specificity
- Supratentorial Neoplasms
- Surface Plasmon Resonance
- Surgical Wound Infection
- Survival
- Survival Analysis
- Survival Rate
- Swiss 3T3 Cells
- T-Lymphocyte Subsets
- T-Lymphocytes
- T-Lymphocytes, Cytotoxic
- T-Lymphocytes, Regulatory
- Tenascin
- Th2 Cells
- Thiazoles
- Thrombocytopenia
- Time Factors
- Tissue Distribution
- Titrimetry
- Tomography, Emission-Computed
- Tomography, Emission-Computed, Single-Photon
- Tomography, X-Ray Computed
- Transfection
- Transforming Growth Factor alpha
- Transforming Growth Factor beta
- Transplantation, Heterologous
- Treatment
- Treatment Failure
- Treatment Outcome
- Trigeminal Nerve
- Tuberculosis, Multidrug-Resistant
- Tuberculosis, Pulmonary
- Tumor Burden
- Tumor Cells, Cultured
- Tumor Escape
- Tumor Markers, Biological
- Tumor Microenvironment
- Tumor Suppressor Proteins
- Tyrosine
- Tyrphostins
- United States
- Urban Population
- Vaccination
- Vaccines, Subunit
- Vascular Endothelial Growth Factor A
- Viremia
- Virulence Factors
- Work Schedule Tolerance
- Xenograft Model Antitumor Assays
- Young Adult
-
Global Scholarship
-
Expertise
-
- Research
-
Selected Grants
- ATRXmutations,innate immune activation and therapeutic vunerabilityin malignant gliomas awarded by National Institutes of Health 2022 - 2027
- Medical Scientist Training Program awarded by National Institutes of Health 2022 - 2027
- University Training Program in Biomolecular and Tissue Engineering awarded by National Institutes of Health 1994 - 2027
- Clinical Neuroimmunology of Vaccines in Brain Tumors awarded by National Institutes of Health 2021 - 2025
- Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma awarded by National Institutes of Health 2021 - 2025
- NINDS Research Education Programs for Residents and Fellows in Neurosurgery awarded by National Institutes of Health 2009 - 2025
- Basic Immunology Training Program awarded by National Institutes of Health 2022 - 2025
- Duke SPORE in Brain Cancer awarded by National Institutes of Health 2014 - 2024
- Viral Oncology Training Grant awarded by National Institutes of Health 1980 - 2024
- Mechanisms and Clinical Impact of Myocardial Injury Following Traumatic Brain Injury awarded by National Institutes of Health 2019 - 2024
- Advanced Immunobiology Traning Program for Surgeons awarded by National Institutes of Health 2019 - 2024
- Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy awarded by National Institutes of Health 2018 - 2023
- Experimental Therapy for Brain Tumors awarded by National Institutes of Health 2018 - 2023
- Metabolic reprogramming to improve EGFRvIII CAR T cell persistence awarded by University of North Carolina - Chapel Hill 2023
- Creating the next generation peptide vaccine directed at cytomegalovirus antigens in malignant brain awarded by National Pediatric Cancer Foundation, Inc. 2022 - 2023
- Metabolic reprogramming to improve EGFRvIII CAR T cell persistence awarded by National Institutes of Health 2021 - 2023
- Human EGFRvIII-specific BiTE for the treatment of Glioblastoma awarded by National Institutes of Health 2015 - 2023
- Cabinet Radiation Therapy System for Small Animals awarded by North Carolina Biotechnology Center 2022 - 2023
- BATF3+ Dendritic Cells for the Treatment of Malignant Gliomas awarded by Department of Defense 2020 - 2022
- Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2022
- T32 UNC - Duke Immunotherapy Training Program awarded by University of North Carolina - Chapel Hill 2021 - 2022
- The Role of CD155 in Leptomeningeal Dissemination and Oncolytic Virus Susceptibility in the Medulloblastoma Microenvironment awarded by Department of Defense 2018 - 2022
- Image-Guided Radiation Therapy System for Small Animals awarded by National Institutes of Health 2021 - 2022
- Medical Scientist Training Program awarded by National Institutes of Health 1997 - 2022
- Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma? awarded by National Institutes of Health 2019 - 2022
- PBTF Institute Grant awarded by Pediatric Brain Tumor Foundation 2015 - 2021
- CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy awarded by National Institutes of Health 2016 - 2021
- Improving CAR T cell immunotherapy for heterogeneous brain tumors awarded by University of Florida 2019 - 2021
- Efficacy of dendritic cell vaccines targeting CMV antigens in glioblastoma awarded by University of Florida 2017 - 2021
- Quantitative Staging and Therapeutic Response in IDH-1 Mutated Glioblastomas awarded by National Institutes of Health 2017 - 2021
- EGFRvIII-targeted Bispecific T cell Engagers for brain tumors awarded by National Institutes of Health 2013 - 2019
- Development of a Therapeutic for Brain Tumor Immunotherapy awarded by National Institutes of Health 2018 - 2019
- Systemically administrered EGRFvIII-targeted bispecific antibody as an immunotherapeutic for glioblastoma. awarded by National Institutes of Health 2015 - 2019
- Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells awarded by National Institutes of Health 2013 - 2018
- Loglio Project awarded by University of California - San Francisco 2016 - 2018
- Brain Tumor Targeting Using Tumor-Specific Neuroimmunology awarded by National Institutes of Health 2014 - 2018
- Targeting Translation Control in Malignant Glioma awarded by National Institutes of Health 2007 - 2018
- A clinically-relevant anti-CD27 agonist antibody as a vaccine adjuvant for brain tumor immunotherapy awarded by National Institutes of Health 2016 - 2017
- Enhancing dendritic cell migration to drive potent anti-tumor immune responses awarded by National Institutes of Health 2013 - 2017
- Use of YH24931 in combination with antigen-specific DC vaccines for antitumor efficacy awarded by Yuhan Corporation 2016 - 2017
- Pediatric Brain Tumor Consortium awarded by St. Jude Children's Research Hospital 2014 - 2017
- Research Training In Neuro-Oncology awarded by National Institutes of Health 1998 - 2016
- HFTL event awarded by BrainLAB, Inc. 2016
- Cancer Biology Training Grant awarded by National Cancer Institute 1993 - 2016
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
- Development of peptide vaccine for diffuse intrinsic pontine glioma awarded by The Cure Starts Now 2013 - 2014
- Convection Enhanced Delivery of Chemokines can increase T-Cell Chemotaxis to Brain Tumors in an Adoptive T cell Model awarded by American Brain Tumor Association 2014
- Targeting EGFRvIII in Brain Tumors with Bispecific Antibodies awarded by National Institutes of Health 2013 - 2014
- Modulation of the blood-tumor barrier through targeted suppression of claudin 5 awarded by National Institutes of Health 2011 - 2013
- RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells awarded by National Institutes of Health 2008 - 2013
- Enterovirus Vectors with Respiratory Tropism for Cancer Immunotherapy awarded by National Institutes of Health 2009 - 2012
- Neuroimmunology of Vaccines in Adoptive T-cell Therapy for Brain Tumor awarded by National Institutes of Health 2010 - 2012
- Pre-clinical Translation of Regulatory T-cell Inhibition in Brain Tumors awarded by National Institutes of Health 2010 - 2012
- Gene Targeted Therapy of Brain Tumors awarded by National Institutes of Health 2009 - 2012
- Research Training In Neuro-Oncology awarded by National Institutes of Health 2005 - 2010
- Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant Gliomas awarded by National Institutes of Health 2008 - 2009
- Dendritic Cell Immunotherapy of Malignant Gliomas awarded by National Institutes of Health 2002 - 2008
- Intracerebral Infusion of Radiolabeled Specific Antibody awarded by National Institutes of Health 2002 - 2008
- Regional AGT Depletion of CNS and Leptomeningeal Tumors awarded by National Institutes of Health 2002 - 2006
- GCRC CAP awarded by National Institutes of Health 2000 - 2005
-
External Relationships
- Annias Immunotherapeutics, Inc.
- Celldex
- Centuar Bio
- Clario Blue Earth
- Cognos Therapeutics
- Creosalus
- Immunomic Therapeutics
- Insera health
- Istari Oncology
- Medicenna Therapeutics
- Myeloid TX
- Neuronium
- Shorla
- Publications & Artistic Works
-
Selected Publications
-
Books
-
Sampson, J. H. Translational Immunotherapy of Brain Tumors, 2017.
-
Swartz, A. M., T. H. Schaller, and J. H. Sampson. Introduction to Translational Immunotherapy for Brain Tumors, 2017. https://doi.org/10.1016/B978-0-12-802420-1.02001-9.Full Text
-
Sampson, J. H., D. D. Bigner, A. H. Friedman, H. S. Friedman, and R. McLendon. The Duke glioma handbook: Pathology, diagnosis, and management, 2016. https://doi.org/10.1017/CBO9781107588721.Full Text
-
-
Academic Articles
-
Sampson, John H., Achal Singh Achrol, Manish K. Aghi, Krystof Bankiewicz, Martin Bexon, Steven Brem, Andrew Brenner, et al. “Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.” Neuro Oncol 25, no. 6 (June 2, 2023): 1085–97. https://doi.org/10.1093/neuonc/noac285.Full Text Link to Item
-
Toro, Camilo, Tetsu Ohnuma, Jordan Komisarow, Monica S. Vavilala, Daniel T. Laskowitz, Michael L. James, Joseph P. Mathew, et al. “Early Vasopressor Utilization Strategies and Outcomes in Critically Ill Patients With Severe Traumatic Brain Injury.” Anesth Analg 135, no. 6 (December 1, 2022): 1245–52. https://doi.org/10.1213/ANE.0000000000005949.Full Text Link to Item
-
Tomaszewski, William H., Jessica Waibl-Polania, Molly Chakraborty, Jonathan Perera, Jeremy Ratiu, Alexandra Miggelbrink, Donald P. McDonnell, et al. “Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma.” Nat Commun 13, no. 1 (October 29, 2022): 6483. https://doi.org/10.1038/s41467-022-34175-y.Full Text Link to Item
-
Toro, Camilo, Jordan Hatfield, Nancy Temkin, Jason Barber, Geoffrey Manley, Tetsu Ohnuma, Jordan Komisarow, et al. “Risk Factors and Neurological Outcomes Associated With Circulatory Shock After Moderate-Severe Traumatic Brain Injury: A TRACK-TBI Study.” Neurosurgery 91, no. 3 (September 1, 2022): 427–36. https://doi.org/10.1227/neu.0000000000002042.Full Text Link to Item
-
Wu, Yaoying, Hanning Wen, Zachary J. Bernstein, Kelly M. Hainline, Tykia S. Blakney, Kendra L. Congdon, David J. Snyder, John H. Sampson, Luis Sanchez-Perez, and Joel H. Collier. “Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses.” Sci Adv 8, no. 29 (July 22, 2022): eabm7833. https://doi.org/10.1126/sciadv.abm7833.Full Text Link to Item
-
Komisarow, Jordan M., Camilo Toro, Jonathan Curley, Brianna Mills, Christopher Cho, Georges Motchoffo Simo, Monica S. Vavilala, et al. “Utilization of Brain Tissue Oxygenation Monitoring and Association with Mortality Following Severe Traumatic Brain Injury.” Neurocrit Care 36, no. 2 (April 2022): 350–56. https://doi.org/10.1007/s12028-021-01394-y.Full Text Open Access Copy Link to Item
-
Bagley, Stephen J., Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, et al. “Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.” Clin Cancer Res 28, no. 4 (February 15, 2022): 594–602. https://doi.org/10.1158/1078-0432.CCR-21-2750.Full Text Link to Item
-
Singh, Kirit, Kristen A. Batich, Patrick Y. Wen, Aaron C. Tan, Stephen J. Bagley, Michael Lim, Michael Platten, et al. “Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.” Clin Cancer Res 28, no. 4 (February 15, 2022): 585–93. https://doi.org/10.1158/1078-0432.CCR-21-2681.Full Text Link to Item
-
Toro, Camilo, Nancy Temkin, Jason Barber, Geoffrey Manley, Sonia Jain, Tetsu Ohnuma, Jordan Komisarow, et al. “Association of Vasopressor Choice with Clinical and Functional Outcomes Following Moderate to Severe Traumatic Brain Injury: A TRACK-TBI Study.” Neurocrit Care 36, no. 1 (February 2022): 180–91. https://doi.org/10.1007/s12028-021-01280-7.Full Text Link to Item
-
Omuro, Antonio, David A. Reardon, John H. Sampson, Joachim Baehring, Solmaz Sahebjam, Timothy F. Cloughesy, Alexandros-Georgios Chalamandaris, Von Potter, Nicholas Butowski, and Michael Lim. “Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.” Neurooncol Adv 4, no. 1 (2022): vdac025. https://doi.org/10.1093/noajnl/vdac025.Full Text Link to Item
-
Swartz, Adam M., Kelly M. Hotchkiss, Smita K. Nair, John H. Sampson, and Kristen A. Batich. “Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype.” Methods Mol Biol 2410 (2022): 609–26. https://doi.org/10.1007/978-1-0716-1884-4_33.Full Text Link to Item
-
Tomaszewski, W. H., J. Waibl-Polania, A. M. Miggelbrink, M. A. Chakraborty, P. E. Fecci, J. H. Sampson, and M. D. Gunn. “Broad immunophenotyping of the murine brain tumor microenvironment.” J Immunol Methods 499 (December 2021): 113158. https://doi.org/10.1016/j.jim.2021.113158.Full Text Link to Item
-
Singh, Kirit, Kelly M. Hotchkiss, Aditya A. Mohan, Jessica L. Reedy, John H. Sampson, and Mustafa Khasraw. “For whom the T cells troll? Bispecific T-cell engagers in glioblastoma.” J Immunother Cancer 9, no. 11 (November 2021). https://doi.org/10.1136/jitc-2021-003679.Full Text Link to Item
-
Singh, Kirit, Kelly M. Hotchkiss, Kisha K. Patel, Daniel S. Wilkinson, Aditya A. Mohan, Sarah L. Cook, and John H. Sampson. “Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma.” Cancers (Basel) 13, no. 21 (October 26, 2021). https://doi.org/10.3390/cancers13215367.Full Text Link to Item
-
Krishnamoorthy, Vijay, Nancy Temkin, Jason Barber, Brandon Foreman, Jordan Komisarow, Fred K. Korley, Daniel T. Laskowitz, et al. “Association of Early Multiple Organ Dysfunction With Clinical and Functional Outcomes Over the Year Following Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study.” Crit Care Med 49, no. 10 (October 1, 2021): 1769–78. https://doi.org/10.1097/CCM.0000000000005055.Full Text Link to Item
-
Luu, David, Jordan Komisarow, Brianna M. Mills, Monica S. Vavilala, Daniel T. Laskowitz, Joseph Mathew, Michael L. James, et al. “Association of Severe Acute Kidney Injury with Mortality and Healthcare Utilization Following Isolated Traumatic Brain Injury.” Neurocrit Care 35, no. 2 (October 2021): 434–40. https://doi.org/10.1007/s12028-020-01183-z.Full Text Open Access Copy Link to Item
-
Ellingson, Benjamin M., John Sampson, Achal Singh Achrol, Manish K. Aghi, Krystof Bankiewicz, Chencai Wang, Martin Bexon, et al. “Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.” Clin Cancer Res 27, no. 14 (July 15, 2021): 3916–25. https://doi.org/10.1158/1078-0432.CCR-21-0446.Full Text Link to Item
-
Swartz, Adam M., Kendra L. Congdon, Smita K. Nair, Qi-Jing Li, James E. Herndon, Carter M. Suryadevara, Katherine A. Riccione, et al. “A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.” Npj Vaccines 6, no. 1 (January 18, 2021): 12. https://doi.org/10.1038/s41541-020-00273-5.Full Text Open Access Copy Link to Item
-
Gromeier, Matthias, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, et al. “Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.” Nat Commun 12, no. 1 (January 13, 2021): 352. https://doi.org/10.1038/s41467-020-20469-6.Full Text Open Access Copy Link to Item
-
Hotchkiss, Kelly M., and John H. Sampson. “Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.” J Neurooncol 151, no. 1 (January 2021): 55–62. https://doi.org/10.1007/s11060-020-03598-2.Full Text Link to Item
-
Kim, Grace J., Evan D. Buckley, James E. Herndon, Karen J. Allen, Tyketra S. Dale, Justus D. Adamson, Lam Lay, et al. “Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study.” Adv Radiat Oncol 6, no. 6 (2021): 100760. https://doi.org/10.1016/j.adro.2021.100760.Full Text Link to Item
-
Mohan, Aditya A., William H. Tomaszewski, Aden P. Haskell-Mendoza, Kelly M. Hotchkiss, Kirit Singh, Jessica L. Reedy, Peter E. Fecci, John H. Sampson, and Mustafa Khasraw. “Targeting Immunometabolism in Glioblastoma.” Front Oncol 11 (2021): 696402. https://doi.org/10.3389/fonc.2021.696402.Full Text Link to Item
-
Batich, Kristen A., Duane A. Mitchell, Patrick Healy, James E. Herndon, and John H. Sampson. “Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.” Clin Cancer Res 26, no. 20 (October 15, 2020): 5297–5303. https://doi.org/10.1158/1078-0432.CCR-20-1082.Full Text Link to Item
-
Khasraw, Mustafa, David A. Reardon, Michael Weller, and John H. Sampson. “PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?” Clin Cancer Res 26, no. 20 (October 15, 2020): 5287–96. https://doi.org/10.1158/1078-0432.CCR-20-1135.Full Text Link to Item
-
Sampson, J., A. S. Achrol, M. K. Aghi, K. Bankiewicz, M. Bexon, S. Brem, A. Brenner, et al. “MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit.” European Journal of Cancer 138 (October 1, 2020): S6. https://doi.org/10.1016/S0959-8049(20)31084-4.Full Text
-
Gedeon, Patrick C., Cosette D. Champion, Kristen E. Rhodin, Karolina Woroniecka, Hanna R. Kemeny, Alexa N. Bramall, Joshua D. Bernstock, Bryan D. Choi, and John H. Sampson. “Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.” Expert Rev Clin Pharmacol 13, no. 10 (October 2020): 1147–58. https://doi.org/10.1080/17512433.2020.1817737.Full Text Link to Item
-
Brady, M., R. Raghavan, and J. Sampson. “Determinants of intraparenchymal infusion distributions: Modeling and analyses of human glioblastoma trials.” Pharmaceutics 12, no. 9 (September 1, 2020): 1–37. https://doi.org/10.3390/pharmaceutics12090895.Full Text
-
Reardon, David A., Alba A. Brandes, Antonio Omuro, Paul Mulholland, Michael Lim, Antje Wick, Joachim Baehring, et al. “Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.” Jama Oncol 6, no. 7 (July 1, 2020): 1003–10. https://doi.org/10.1001/jamaoncol.2020.1024.Full Text Link to Item
-
Evgin, Laura, Amanda L. Huff, Phonphimon Wongthida, Jill Thompson, Tim Kottke, Jason Tonne, Matthew Schuelke, et al. “Oncolytic virus-derived type I interferon restricts CAR T cell therapy.” Nat Commun 11, no. 1 (June 24, 2020): 3187. https://doi.org/10.1038/s41467-020-17011-z.Full Text Link to Item
-
Wu, Yaoying, Sean H. Kelly, Luis Sanchez-Perez, John H. Sampson, and Joel H. Collier. “Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes.” Biomater Sci 8, no. 12 (June 21, 2020): 3522–35. https://doi.org/10.1039/d0bm00521e.Full Text Link to Item
-
Shen, Steven H., Karolina Woroniecka, Andrew B. Barbour, Peter E. Fecci, Luis Sanchez-Perez, and John H. Sampson. “CAR T cells and checkpoint inhibition for the treatment of glioblastoma.” Expert Opin Biol Ther 20, no. 6 (June 2020): 579–91. https://doi.org/10.1080/14712598.2020.1727436.Full Text Link to Item
-
Moravan, Michael J., Peter E. Fecci, Carey K. Anders, Jeffrey M. Clarke, April K. S. Salama, Justus D. Adamson, Scott R. Floyd, et al. “Current multidisciplinary management of brain metastases.” Cancer 126, no. 7 (April 1, 2020): 1390–1406. https://doi.org/10.1002/cncr.32714.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, Donald M. O’Rourke, David D. Tran, Karen L. Fink, Louis B. Nabors, et al. “Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.” Clin Cancer Res 26, no. 7 (April 1, 2020): 1586–94. https://doi.org/10.1158/1078-0432.CCR-18-1140.Full Text Link to Item
-
Schaller, Teilo H., David J. Snyder, Ivan Spasojevic, Patrick C. Gedeon, Luis Sanchez-Perez, and John H. Sampson. “First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.” J Immunother Cancer 8, no. 1 (April 2020). https://doi.org/10.1136/jitc-2019-000213.Full Text Link to Item
-
Huang, Min-Nung, Lowell T. Nicholson, Kristen A. Batich, Adam M. Swartz, David Kopin, Sebastian Wellford, Vijay K. Prabhakar, et al. “Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses.” J Clin Invest 130, no. 2 (February 3, 2020): 774–88. https://doi.org/10.1172/JCI128267.Full Text Link to Item
-
Gedeon, Patrick C., Michael A. Streicker, Teilo H. Schaller, Gary E. Archer, Micheal P. Jokinen, and John H. Sampson. “GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody.” Plos One 15, no. 7 (2020): e0236374. https://doi.org/10.1371/journal.pone.0236374.Full Text Link to Item
-
Sampson, John H., Michael D. Gunn, Peter E. Fecci, and David M. Ashley. “Brain immunology and immunotherapy in brain tumours.” Nat Rev Cancer 20, no. 1 (January 2020): 12–25. https://doi.org/10.1038/s41568-019-0224-7.Full Text Link to Item
-
Fecci, Peter E., Cosette D. Champion, Jacob Hoj, Courtney M. McKernan, C Rory Goodwin, John P. Kirkpatrick, Carey K. Anders, Ann Marie Pendergast, and John H. Sampson. “The Evolving Modern Management of Brain Metastasis.” Clin Cancer Res 25, no. 22 (November 15, 2019): 6570–80. https://doi.org/10.1158/1078-0432.CCR-18-1624.Full Text Link to Item
-
Fecci, Peter E., and John H. Sampson. “The current state of immunotherapy for gliomas: an eye toward the future.” J Neurosurg 131, no. 3 (September 1, 2019): 657–66. https://doi.org/10.3171/2019.5.JNS181762.Full Text Link to Item
-
Schaller, Teilo H., Matthew W. Foster, J Will Thompson, Ivan Spasojevic, Deimante Normantaite, M Arthur Moseley, Luis Sanchez-Perez, and John H. Sampson. “Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach.” J Proteome Res 18, no. 8 (August 2, 2019): 3032–41. https://doi.org/10.1021/acs.jproteome.9b00145.Full Text Link to Item
-
Aldape, Kenneth, Kevin M. Brindle, Louis Chesler, Rajesh Chopra, Amar Gajjar, Mark R. Gilbert, Nicholas Gottardo, et al. “Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.” Nat Rev Clin Oncol 16, no. 8 (August 2019): 522–23. https://doi.org/10.1038/s41571-019-0236-y.Full Text Link to Item
-
Aldape, Kenneth, Kevin M. Brindle, Louis Chesler, Rajesh Chopra, Amar Gajjar, Mark R. Gilbert, Nicholas Gottardo, et al. “Challenges to curing primary brain tumours.” Nat Rev Clin Oncol 16, no. 8 (August 2019): 509–20. https://doi.org/10.1038/s41571-019-0177-5.Full Text Link to Item
-
Tomaszewski, William, Luis Sanchez-Perez, Thomas F. Gajewski, and John H. Sampson. “Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.” Clin Cancer Res 25, no. 14 (July 15, 2019): 4202–10. https://doi.org/10.1158/1078-0432.CCR-18-1627.Full Text Link to Item
-
Hansen, Landon J., Ran Sun, Rui Yang, Simranjit X. Singh, Lee H. Chen, Christopher J. Pirozzi, Casey J. Moure, et al. “MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.” Cancer Res 79, no. 13 (July 1, 2019): 3383–94. https://doi.org/10.1158/0008-5472.CAN-18-1010.Full Text Link to Item
-
Congdon, Kendra L., Luis A. Sanchez-Perez, and John H. Sampson. “Effective effectors: How T cells access and infiltrate the central nervous system.” Pharmacol Ther 197 (May 2019): 52–60. https://doi.org/10.1016/j.pharmthera.2018.12.007.Full Text Link to Item
-
Choi, Bryan D., Marcela V. Maus, Carl H. June, and John H. Sampson. “Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.” Clin Cancer Res 25, no. 7 (April 1, 2019): 2042–48. https://doi.org/10.1158/1078-0432.CCR-18-1625.Full Text Link to Item
-
Desjardins, Annick, James E. Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, et al. “Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.” Health Sci Rep 2, no. 4 (April 2019): e114. https://doi.org/10.1002/hsr2.114.Full Text Link to Item
-
Chongsathidkiet, Pakawat, Christina Jackson, Shohei Koyama, Franziska Loebel, Xiuyu Cui, S Harrison Farber, Karolina Woroniecka, et al. “Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.” Nat Med 25, no. 3 (March 2019): 529. https://doi.org/10.1038/s41591-019-0355-0.Full Text Link to Item
-
Suryadevara, Carter M., Rupen Desai, S Harrison Farber, Bryan D. Choi, Adam M. Swartz, Steven H. Shen, Patrick C. Gedeon, et al. “Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.” Clin Cancer Res 25, no. 1 (January 1, 2019): 358–68. https://doi.org/10.1158/1078-0432.CCR-18-1211.Full Text Link to Item
-
Elsamadicy, Aladine A., Amanda Sergesketter, John H. Sampson, and Oren N. Gottfried. “Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients: Are We Improving?” Neurosurgery 83, no. 6 (December 1, 2018): 1269–76. https://doi.org/10.1093/neuros/nyx603.Full Text Link to Item
-
Atik, Ahmet F., Carter M. Suryadevara, Ryan M. Schweller, Jennifer L. West, Patrick Healy, James E. Herndon Ii, Kendra L. Congdon, et al. “Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells.” J Clin Neurosci 56 (October 2018): 163–68. https://doi.org/10.1016/j.jocn.2018.06.005.Full Text Link to Item
-
Chongsathidkiet, Pakawat, Christina Jackson, Shohei Koyama, Franziska Loebel, Xiuyu Cui, S Harrison Farber, Karolina Woroniecka, et al. “Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.” Nat Med 24, no. 9 (September 2018): 1459–68. https://doi.org/10.1038/s41591-018-0135-2.Full Text Link to Item
-
Gedeon, Patrick C., Teilo H. Schaller, Satish K. Chitneni, Bryan D. Choi, Chien-Tsun Kuan, Carter M. Suryadevara, David J. Snyder, et al. “A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.” Clin Cancer Res 24, no. 15 (August 1, 2018): 3611–31. https://doi.org/10.1158/1078-0432.CCR-17-0126.Full Text Link to Item
-
Swartz, Adam M., Elizabeth Reap, Pamela Norberg, Robert Schmittling, Sylvia Janetzki, Luis Sanchez-Perez, and John H. Sampson. “A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis.” J Immunol Methods 459 (August 2018): 90–93. https://doi.org/10.1016/j.jim.2018.05.015.Full Text Link to Item
-
Desjardins, Annick, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, et al. “Recurrent Glioblastoma Treated with Recombinant Poliovirus.” N Engl J Med 379, no. 2 (July 12, 2018): 150–61. https://doi.org/10.1056/NEJMoa1716435.Full Text Link to Item
-
Colman, Howard, Manfred Westphal, and John H. Sampson. “Introduction. Update on adult neuro-oncology.” Neurosurg Focus 44, no. 6 (June 2018): E1. https://doi.org/10.3171/2018.3.FOCUS18149.Full Text Link to Item
-
Omuro, Antonio, Gordana Vlahovic, Michael Lim, Solmaz Sahebjam, Joachim Baehring, Timothy Cloughesy, Alfredo Voloschin, et al. “Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.” Neuro Oncol 20, no. 5 (April 9, 2018): 674–86. https://doi.org/10.1093/neuonc/nox208.Full Text Link to Item
-
Reap, Elizabeth A., Carter M. Suryadevara, Kristen A. Batich, Luis Sanchez-Perez, Gary E. Archer, Robert J. Schmittling, Pamela K. Norberg, et al. “Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.” Cancer Res 78, no. 1 (January 1, 2018): 256–64. https://doi.org/10.1158/0008-5472.CAN-17-0469.Full Text Link to Item
-
Riccione, Katherine A., Li-Zhen He, Peter E. Fecci, Pamela K. Norberg, Carter M. Suryadevara, Adam Swartz, Patrick Healy, et al. “CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response.” Oncoimmunology 7, no. 12 (2018): e1502904. https://doi.org/10.1080/2162402X.2018.1502904.Full Text Link to Item
-
Suryadevara, Carter M., Rupen Desai, Melissa L. Abel, Katherine A. Riccione, Kristen A. Batich, Steven H. Shen, Pakawat Chongsathidkiet, et al. “Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.” Oncoimmunology 7, no. 6 (2018): e1434464. https://doi.org/10.1080/2162402X.2018.1434464.Full Text Open Access Copy Link to Item
-
Wu, Yaoying, Pamela K. Norberg, Elizabeth A. Reap, Kendra L. Congdon, Chelsea N. Fries, Sean H. Kelly, John H. Sampson, Vincent P. Conticello, and Joel H. Collier. “A Supramolecular Vaccine Platform Based on α-Helical Peptide Nanofibers.” Acs Biomater Sci Eng 3, no. 12 (December 11, 2017): 3128–32. https://doi.org/10.1021/acsbiomaterials.7b00561.Full Text Link to Item
-
Weller, Michael, Nicholas Butowski, David D. Tran, Lawrence D. Recht, Michael Lim, Hal Hirte, Lynn Ashby, et al. “Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.” Lancet Oncol 18, no. 12 (December 2017): e709–10. https://doi.org/10.1016/S1470-2045(17)30856-2.Full Text Link to Item
-
Sampson, John H., Michael M. Haglund, Allan H. Friedman, and Matthew G. Ewend. “Obituary. Robert H. Wilkins, MD, 1934-2017.” J Neurosurg 127, no. 6 (December 2017): 1457–58. https://doi.org/10.3171/2017.6.JNS171416.Full Text Link to Item
-
Schaller, Teilo H., Kristen A. Batich, Carter M. Suryadevara, Rupen Desai, and John H. Sampson. “Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.” Expert Rev Clin Immunol 13, no. 11 (November 2017): 1049–60. https://doi.org/10.1080/1744666X.2017.1384313.Full Text Link to Item
-
Aliabadi, H., A. M. Nikpour, D. S. Yoo, J. E. Herndon, J. H. Sampson, and J. P. Kirkpatrick. “Pre-operative stereotactic radiosurgery treatment is preferred to post-operative treatment for smaller solitary brain metastases.” Chinese Neurosurgical Journal 3, no. 1 (October 3, 2017). https://doi.org/10.1186/s41016-017-0092-5.Full Text
-
Narloch, Jessica L., S Harrison Farber, Sarah Sammons, Frances McSherry, James E. Herndon, Jenny K. Hoang, Fang-Fang Yin, et al. “Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.” Neuro Oncol 19, no. 10 (October 1, 2017): 1391–97. https://doi.org/10.1093/neuonc/nox090.Full Text Link to Item
-
Sankey, Eric W., Eric Butler, and John H. Sampson. “Accuracy of Novel Computed Tomography-Guided Frameless Stereotactic Drilling and Catheter System in Human Cadavers.” World Neurosurgery 106 (October 2017): 757–63. https://doi.org/10.1016/j.wneu.2017.07.098.Full Text
-
Weller, Michael, Nicholas Butowski, David D. Tran, Lawrence D. Recht, Michael Lim, Hal Hirte, Lynn Ashby, et al. “Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.” Lancet Oncol 18, no. 10 (October 2017): 1373–85. https://doi.org/10.1016/S1470-2045(17)30517-X.Full Text Link to Item
-
Sampson, John H., Marcela V. Maus, and Carl H. June. “Immunotherapy for Brain Tumors.” J Clin Oncol 35, no. 21 (July 20, 2017): 2450–56. https://doi.org/10.1200/JCO.2017.72.8089.Full Text Link to Item
-
Ewend, Matthew G., Allan H. Friedman, and John H. Sampson. “In Memoriam: Robert H. Wilkins, MD, 1934 to 2017.” Neurosurgery 81, no. 1 (July 1, 2017): 6–8. https://doi.org/10.1093/neuros/nyx283.Full Text Link to Item
-
Reardon, David A., Patrick Y. Wen, Kai W. Wucherpfennig, and John H. Sampson. “Immunomodulation for glioblastoma.” Curr Opin Neurol 30, no. 3 (June 2017): 361–69. https://doi.org/10.1097/WCO.0000000000000451.Full Text Link to Item
-
Weller, Michael, Patrick Roth, Matthias Preusser, Wolfgang Wick, David A. Reardon, Michael Platten, and John H. Sampson. “Vaccine-based immunotherapeutic approaches to gliomas and beyond.” Nat Rev Neurol 13, no. 6 (June 2017): 363–74. https://doi.org/10.1038/nrneurol.2017.64.Full Text Link to Item
-
Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, et al. “Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.” Clin Cancer Res 23, no. 8 (April 15, 2017): 1898–1909. https://doi.org/10.1158/1078-0432.CCR-16-2057.Full Text Link to Item
-
Elsamadicy, Aladine A., Pakawat Chongsathidkiet, Rupen Desai, Karolina Woroniecka, S Harrison Farber, Peter E. Fecci, and John H. Sampson. “Prospect of rindopepimut in the treatment of glioblastoma.” Expert Opin Biol Ther 17, no. 4 (April 2017): 507–13. https://doi.org/10.1080/14712598.2017.1299705.Full Text Link to Item
-
Walicke, Patricia, Aviva Abosch, Anthony Asher, Fred G. Barker, Zoher Ghogawala, Robert Harbaugh, Lara Jehi, et al. “Launching Effectiveness Research to Guide Practice in Neurosurgery: A National Institute Neurological Disorders and Stroke Workshop Report.” Neurosurgery 80, no. 4 (April 1, 2017): 505–14. https://doi.org/10.1093/neuros/nyw133.Full Text Link to Item
-
Farber, S Harrison, Aladine A. Elsamadicy, Ahmet Fatih Atik, Carter M. Suryadevara, Pakawat Chongsathidkiet, Peter E. Fecci, and John H. Sampson. “The Safety of available immunotherapy for the treatment of glioblastoma.” Expert Opin Drug Saf 16, no. 3 (March 2017): 277–87. https://doi.org/10.1080/14740338.2017.1273898.Full Text Link to Item
-
Thompson, Eric M., Sridharan Gururangan, Gerald Grant, Duane Mitchell, and John H. Sampson. “The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial.” J Neurooncol 132, no. 1 (March 2017): 83–87. https://doi.org/10.1007/s11060-016-2338-z.Full Text Link to Item
-
Berger, Miles, Vikram Ponnusamy, Nathaniel Greene, Mary Cooter, Jacob W. Nadler, Allan Friedman, David L. McDonagh, et al. “The Effect of Propofol vs. Isoflurane Anesthesia on Postoperative Changes in Cerebrospinal Fluid Cytokine Levels: Results from a Randomized Trial.” Front Immunol 8 (2017): 1528. https://doi.org/10.3389/fimmu.2017.01528.Full Text Link to Item
-
Limon, Dror, Frances McSherry, James Herndon, John Sampson, Peter Fecci, Justus Adamson, Zhiheng Wang, et al. “Single fraction stereotactic radiosurgery for multiple brain metastases.” Adv Radiat Oncol 2, no. 4 (2017): 555–63. https://doi.org/10.1016/j.adro.2017.09.002.Full Text Open Access Copy Link to Item
-
Sayour, Elias J., Gabriel De Leon, Christina Pham, Adam Grippin, Hanna Kemeny, Joshua Chua, Jianping Huang, et al. “Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.” Oncoimmunology 6, no. 1 (2017): e1256527. https://doi.org/10.1080/2162402X.2016.1256527.Full Text Link to Item
-
Schaller, Teilo H., and John H. Sampson. “Advances and challenges: dendritic cell vaccination strategies for glioblastoma.” Expert Rev Vaccines 16, no. 1 (January 2017): 27–36. https://doi.org/10.1080/14760584.2016.1218762.Full Text Link to Item
-
Suryadevara, Carter M., Katherine A. Riccione, and John H. Sampson. “Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.” Clin Cancer Res 22, no. 21 (November 1, 2016): 5164–66. https://doi.org/10.1158/1078-0432.CCR-16-1666.Full Text Link to Item
-
Li, Fang, Xinjian Liu, John H. Sampson, Darell D. Bigner, and Chuan-Yuan Li. “Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors.” Cancer Res 76, no. 17 (September 1, 2016): 5143–50. https://doi.org/10.1158/0008-5472.CAN-16-0171.Full Text Link to Item
-
Suryadevara, Carter M., Rupen Desai, Samuel Harrison Farber, Patrick C. Gedeon, Adam Swartz, David Snyder, James Herndon, et al. “369 Chimeric Antigen Receptors Deficient in Lck Signaling Require 4-1BB Costimulation to Expand in Vivo, Resist Regulatory T-Cell Suppression, and Treat Solid Tumors in Immune-Intact Hosts.” Neurosurgery 63 Suppl 1 (August 2016): 209–10. https://doi.org/10.1227/01.neu.0000489857.70440.98.Full Text Link to Item
-
Raghavan, Raghu, Martin L. Brady, and John H. Sampson. “Delivering therapy to target: improving the odds for successful drug development.” Ther Deliv 7, no. 7 (July 2016): 457–81. https://doi.org/10.4155/tde-2016-0016.Full Text Link to Item
-
Desai, Rupen, Carter M. Suryadevara, Kristen A. Batich, S Harrison Farber, Luis Sanchez-Perez, and John H. Sampson. “Emerging immunotherapies for glioblastoma.” Expert Opin Emerg Drugs 21, no. 2 (June 2016): 133–45. https://doi.org/10.1080/14728214.2016.1186643.Full Text Link to Item
-
Berger, Miles, Jacob W. Nadler, Allan Friedman, David L. McDonagh, Ellen R. Bennett, Mary Cooter, Wenjing Qi, et al. “The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer's Disease: Results of a Randomized Trial.” J Alzheimers Dis 52, no. 4 (April 15, 2016): 1299–1310. https://doi.org/10.3233/JAD-151190.Full Text Open Access Copy Link to Item
-
Pham, Christina D., Catherine Flores, Changlin Yang, Elaine M. Pinheiro, Jennifer H. Yearley, Elias J. Sayour, Yanxin Pei, et al. “Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.” Clin Cancer Res 22, no. 3 (February 1, 2016): 582–95. https://doi.org/10.1158/1078-0432.CCR-15-0713.Full Text Link to Item
-
Saraswathula, Anirudh, Elizabeth A. Reap, Bryan D. Choi, Robert J. Schmittling, Pamela K. Norberg, Elias J. Sayour, James E. Herndon, et al. “Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.” Cancer Immunol Immunother 65, no. 2 (February 2016): 205–11. https://doi.org/10.1007/s00262-015-1784-3.Full Text Link to Item
-
Sampson, John H. “Alternating Electric Fields for the Treatment of Glioblastoma.” Jama 314, no. 23 (December 15, 2015): 2511–13. https://doi.org/10.1001/jama.2015.16701.Full Text Link to Item
-
Okada, Hideho, Michael Weller, Raymond Huang, Gaetano Finocchiaro, Mark R. Gilbert, Wolfgang Wick, Benjamin M. Ellingson, et al. “Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.” Lancet Oncol 16, no. 15 (November 2015): e534–42. https://doi.org/10.1016/S1470-2045(15)00088-1.Full Text Link to Item
-
Sampson, John H., and Duane A. Mitchell. “Vaccination strategies for neuro-oncology.” Neuro Oncol 17 Suppl 7, no. Suppl 7 (November 2015): vii15–25. https://doi.org/10.1093/neuonc/nov159.Full Text Link to Item
-
Babu, Ranjith, and John H. Sampson. “Patient validation of retrospective data.” J Neurosurg 123, no. 4 (October 2015): 969–70. https://doi.org/10.3171/2015.3.JNS142959.Full Text Link to Item
-
Nair, Smita K., Timothy Driscoll, David Boczkowski, Robert Schmittling, Renee Reynolds, Laura A. Johnson, Gerald Grant, et al. “Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.” J Neurooncol 125, no. 1 (October 2015): 65–74. https://doi.org/10.1007/s11060-015-1890-2.Full Text Link to Item
-
Preusser, Matthias, Michael Lim, David A. Hafler, David A. Reardon, and John H. Sampson. “Prospects of immune checkpoint modulators in the treatment of glioblastoma.” Nat Rev Neurol 11, no. 9 (September 2015): 504–14. https://doi.org/10.1038/nrneurol.2015.139.Full Text Link to Item
-
Choi, Bryan D., Peter E. Fecci, and John H. Sampson. “Editorial: Not everything that matters can be measured and not everything that can be measured matters.” J Neurosurg 123, no. 3 (September 2015): 543–44. https://doi.org/10.3171/2015.2.JNS142977.Full Text Link to Item
-
Vlahovic, Gordana, Peter E. Fecci, David Reardon, and John H. Sampson. “Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.” Neuro Oncol 17, no. 8 (August 2015): 1043–45. https://doi.org/10.1093/neuonc/nov071.Full Text Link to Item
-
Swartz, Adam M., Kristen A. Batich, Peter E. Fecci, and John H. Sampson. “Peptide vaccines for the treatment of glioblastoma.” J Neurooncol 123, no. 3 (July 2015): 433–40. https://doi.org/10.1007/s11060-014-1676-y.Full Text Link to Item
-
Brown, Kristine E., Gustavo Chagoya, Shawn G. Kwatra, Timothy Yen, Stephen T. Keir, Mary Cooter, Katherine A. Hoadley, et al. “Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.” J Neurochem 133, no. 5 (June 2015): 730–38. https://doi.org/10.1111/jnc.13032.Full Text Link to Item
-
Schuster, James, Rose K. Lai, Lawrence D. Recht, David A. Reardon, Nina A. Paleologos, Morris D. Groves, Maciej M. Mrugala, et al. “A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.” Neuro Oncol 17, no. 6 (June 2015): 854–61. https://doi.org/10.1093/neuonc/nou348.Full Text Link to Item
-
Fecci, Peter E., Ranjith Babu, D Cory Adamson, and John H. Sampson. “Editorial: Turning fluorescence into black and white.” J Neurosurg 122, no. 6 (June 2015): 1356–58. https://doi.org/10.3171/2014.10.JNS141788.Full Text Link to Item
-
Suryadevara, Carter M., Patrick C. Gedeon, Luis Sanchez-Perez, Terence Verla, Christopher Alvarez-Breckenridge, Bryan D. Choi, Peter E. Fecci, and John H. Sampson. “Are BiTEs the "missing link" in cancer therapy?” Oncoimmunology 4, no. 6 (June 2015): e1008339. https://doi.org/10.1080/2162402X.2015.1008339.Full Text Link to Item
-
Sayour, Elias J., Pat McLendon, Roger McLendon, Gabriel De Leon, Renee Reynolds, Jesse Kresak, John H. Sampson, and Duane A. Mitchell. “Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.” Cancer Immunol Immunother 64, no. 4 (April 2015): 419–27. https://doi.org/10.1007/s00262-014-1651-7.Full Text Link to Item
-
Mitchell, Duane A., Elias J. Sayour, Elizabeth Reap, Robert Schmittling, Gabriel DeLeon, Pamela Norberg, Annick Desjardins, et al. “Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.” Cancer Immunol Res 3, no. 4 (April 2015): 320–25. https://doi.org/10.1158/2326-6066.CIR-14-0100.Full Text Link to Item
-
Mitchell, Duane A., Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sanchez-Perez, Smita K. Nair, Kendra L. Congdon, et al. “Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.” Nature 519, no. 7543 (March 19, 2015): 366–69. https://doi.org/10.1038/nature14320.Full Text Open Access Copy Link to Item
-
Flores, Catherine, Christina Pham, David Snyder, Shicheng Yang, Luis Sanchez-Perez, Elias Sayour, Xiuyu Cui, et al. “Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.” Oncoimmunology 4, no. 3 (March 2015): e994374. https://doi.org/10.4161/2162402X.2014.994374.Full Text Link to Item
-
Lin, Regina, John H. Sampson, Qi-Jing Li, and Bo Zhu. “miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment.” Oncoimmunology 4, no. 3 (March 2015): e990803. https://doi.org/10.4161/2162402X.2014.990803.Full Text Link to Item
-
Riccione, Katherine, Carter M. Suryadevara, David Snyder, Xiuyu Cui, John H. Sampson, and Luis Sanchez-Perez. “Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.” J Vis Exp, no. 96 (February 16, 2015). https://doi.org/10.3791/52397.Full Text Link to Item
-
Batich, Kristen A., Adam M. Swartz, and John H. Sampson. “Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.” Expert Opin Biol Ther 15, no. 1 (January 2015): 79–94. https://doi.org/10.1517/14712598.2015.972361.Full Text Link to Item
-
Flores, Catherine, Christina Pham, David Snyder, Shicheng Yang, Luis Sanchez-Perez, Elias Sayour, Xiuyu Cui, et al. “Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.” Oncoimmunology 4, no. 3 (2015). https://doi.org/10.4161/2162402X.2014.994374.Full Text Link to Item
-
Kirkpatrick, John P., Zhiheng Wang, John H. Sampson, Frances McSherry, James E. Herndon, Karen J. Allen, Eileen Duffy, et al. “Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial.” Int J Radiat Oncol Biol Phys 91, no. 1 (January 1, 2015): 100–108. https://doi.org/10.1016/j.ijrobp.2014.09.004.Full Text Link to Item
-
Suryadevara, Carter M., Terence Verla, Luis Sanchez-Perez, Elizabeth A. Reap, Bryan D. Choi, Peter E. Fecci, and John H. Sampson. “Immunotherapy for malignant glioma.” Surg Neurol Int 6, no. Suppl 1 (2015): S68–77. https://doi.org/10.4103/2152-7806.151341.Full Text Link to Item
-
Lin, Regina, Ling Chen, Gang Chen, Chunyan Hu, Shan Jiang, Jose Sevilla, Ying Wan, John H. Sampson, Bo Zhu, and Qi-Jing Li. “Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.” J Clin Invest 124, no. 12 (December 2014): 5352–67. https://doi.org/10.1172/JCI76561.Full Text Link to Item
-
Fecci, Peter E., Amy B. Heimberger, and John H. Sampson. “Immunotherapy for primary brain tumors: no longer a matter of privilege.” Clin Cancer Res 20, no. 22 (November 15, 2014): 5620–29. https://doi.org/10.1158/1078-0432.CCR-14-0832.Full Text Link to Item
-
Brown, Michael C., Elena Y. Dobrikova, Mikhail I. Dobrikov, Ross W. Walton, Sarah L. Gemberling, Smita K. Nair, Annick Desjardins, et al. “Oncolytic polio virotherapy of cancer.” Cancer 120, no. 21 (November 1, 2014): 3277–86. https://doi.org/10.1002/cncr.28862.Full Text Link to Item
-
Reardon, David A., Gordon Freeman, Catherine Wu, E Antonio Chiocca, Kai W. Wucherpfennig, Patrick Y. Wen, Edward F. Fritsch, William T. Curry, John H. Sampson, and Glenn Dranoff. “Immunotherapy advances for glioblastoma.” Neuro Oncol 16, no. 11 (November 2014): 1441–58. https://doi.org/10.1093/neuonc/nou212.Full Text Link to Item
-
Kirkpatrick, John P., and John H. Sampson. “Recurrent malignant gliomas.” Semin Radiat Oncol 24, no. 4 (October 2014): 289–98. https://doi.org/10.1016/j.semradonc.2014.06.006.Full Text Link to Item
-
Batich, Kristen A., and John H. Sampson. “Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.” Expert Opin Pharmacother 15, no. 14 (October 2014): 2047–61. https://doi.org/10.1517/14656566.2014.947266.Full Text Link to Item
-
Congdon, Kendra L., Patrick C. Gedeon, Carter M. Suryadevara, Hillary G. Caruso, Laurence J. N. Cooper, Amy B. Heimberger, and John H. Sampson. “Epidermal growth factor receptor and variant III targeted immunotherapy.” Neuro Oncol 16 Suppl 8, no. Suppl 8 (October 2014): viii20–25. https://doi.org/10.1093/neuonc/nou236.Full Text Link to Item
-
Kanaly, Charles W., Ankit I. Mehta, Dale Ding, Jenny K. Hoang, Peter G. Kranz, James E. Herndon, April Coan, et al. “A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.” J Neurosurg 121, no. 3 (September 2014): 536–42. https://doi.org/10.3171/2014.4.JNS121952.Full Text Link to Item
-
Babu, Ranjith, Steven Thomas, Matthew A. Hazzard, Allan H. Friedman, John H. Sampson, Cory Adamson, Ali R. Zomorodi, et al. “Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions.” J Neurosurg 121, no. 2 (August 2014): 262–76. https://doi.org/10.3171/2014.5.JNS1314.Full Text Link to Item
-
Gedeon, Patrick C., Katherine A. Riccione, Peter E. Fecci, and John H. Sampson. “Antibody-based immunotherapy for malignant glioma.” Semin Oncol 41, no. 4 (August 2014): 496–510. https://doi.org/10.1053/j.seminoncol.2014.06.004.Full Text Link to Item
-
Archer, G. E., E. Reap, P. Norberg, X. Cui, R. Schmittling, J. Herndon, V. Chandramohan, et al. “Idh1 mutations as a immunotherapeutic target for brain tumors.” Neuro Oncol 16 Suppl 3 (July 2014): iii40. https://doi.org/10.1093/neuonc/nou208.65.Full Text Link to Item
-
Kwatra, M. M., K. E. Brown, G. Chagoya, S. T. Keir, D. D. Bigner, and J. H. Sampson. “Patient-derived xenografts mirror the proteomic profile of human glioblastoma: implications for personalized drug development.” Neuro Oncol 16 Suppl 3 (July 2014): iii38. https://doi.org/10.1093/neuonc/nou208.57.Full Text Link to Item
-
Desjardins, A., J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.” Neuro Oncol 16 Suppl 3 (July 2014): iii43. https://doi.org/10.1093/neuonc/nou209.5.Full Text Link to Item
-
Nair, Smita K., Gabriel De Leon, David Boczkowski, Robert Schmittling, Weihua Xie, Janet Staats, Rebecca Liu, et al. “Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.” Clin Cancer Res 20, no. 10 (May 15, 2014): 2684–94. https://doi.org/10.1158/1078-0432.CCR-13-3268.Full Text Link to Item
-
Sampson, John H., and Fred G. Barker. “Methodology and reporting of meta-analyses in the neurosurgical literature.” J Neurosurg 120, no. 4 (April 2014): 791–94. https://doi.org/10.3171/2013.10.JNS13724.Full Text Link to Item
-
Choi, Bryan D., Michael R. DeLong, and John H. Sampson. “Response.” J Neurosurg 120, no. 3 (March 2014): 728–29.Link to Item
-
Oyesiku, Nelson M. “Editorial: the impact of PhD training.” J Neurosurg 120, no. 3 (March 2014): 727–28. https://doi.org/10.3171/2013.8.JNS131489.Full Text Link to Item
-
Sampson, John H., Bryan D. Choi, Luis Sanchez-Perez, Carter M. Suryadevara, David J. Snyder, Catherine T. Flores, Robert J. Schmittling, et al. “EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.” Clin Cancer Res 20, no. 4 (February 15, 2014): 972–84. https://doi.org/10.1158/1078-0432.CCR-13-0709.Full Text Link to Item
-
Sampson, John H., Shivanand P. Lad, James E. Herndon, Robert M. Starke, and Douglas Kondziolka. “SEER insights.” J Neurosurg 120, no. 2 (February 2014): 297–98. https://doi.org/10.3171/2013.6.JNS13993.Full Text Link to Item
-
Choi, Bryan D., Carter M. Suryadevara, Patrick C. Gedeon, James E. Herndon, Luis Sanchez-Perez, Darell D. Bigner, and John H. Sampson. “Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.” J Clin Neurosci 21, no. 1 (January 2014): 189–90. https://doi.org/10.1016/j.jocn.2013.03.012.Full Text Link to Item
-
Johnson, Laura A., Luis Sanchez-Perez, Carter M. Suryadevara, and John H. Sampson. “Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.” Oncoimmunology 3, no. 7 (2014): e944059. https://doi.org/10.4161/21624011.2014.944059.Full Text Link to Item
-
Miao, Hongsheng, Bryan D. Choi, Carter M. Suryadevara, Luis Sanchez-Perez, Shicheng Yang, Gabriel De Leon, Elias J. Sayour, et al. “EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.” Plos One 9, no. 4 (2014): e94281. https://doi.org/10.1371/journal.pone.0094281.Full Text Open Access Copy Link to Item
-
Nair, Smita K., John H. Sampson, and Duane A. Mitchell. “Immunological targeting of cytomegalovirus for glioblastoma therapy.” Oncoimmunology 3 (2014): e29289. https://doi.org/10.4161/onci.29289.Full Text Link to Item
-
Sampson, John H., and Gordana Vlahovic. “Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial".” Neuro Oncol 16, no. 2 (January 2014): 169–70. https://doi.org/10.1093/neuonc/not311.Full Text Link to Item
-
Sanchez-Perez, Luis, Carter M. Suryadevara, Bryan D. Choi, Elizabeth A. Reap, and John H. Sampson. “Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.” Oncoimmunology 3, no. 7 (2014): e944054. https://doi.org/10.4161/21624011.2014.944054.Full Text Link to Item
-
Oh, Daniel S., James A. Vredenburgh, David A. Reardon, Leonard R. Prosnitz, Jon P. Gockerman, John H. Sampson, Christopher R. Kelsey, and John P. Kirkpatrick. “Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy.” J Radiosurg Sbrt 3, no. 1 (2014): 37–42.Link to Item
-
Swartz, Adam M., Qi-Jing Li, and John H. Sampson. “Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.” Immunotherapy 6, no. 6 (2014): 679–90. https://doi.org/10.2217/imt.14.21.Full Text Link to Item
-
Choi, B. D., P. C. Gedeon, L. Sanchez-Perez, D. D. Bigner, and J. H. Sampson. “Regulatory T cells are redirected to kill glioblastoma by an EGFRviii-targeted bispecific antibody.” Oncoimmunology 2, no. 12 (December 1, 2013): 1–2. https://doi.org/10.4161/onci.26757.Full Text
-
Choi, Bryan D., Patrick C. Gedeon, Luis Sanchez-Perez, Darell D. Bigner, and John H. Sampson. “Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.” Oncoimmunology 2, no. 12 (December 1, 2013): e26757. https://doi.org/10.4161/onci.26757.Full Text Link to Item
-
Congdon, Kendra L., and John H. Sampson. “Enhanced oncolytic virotherapy through oxidative stress inhibition.” Mol Ther 21, no. 11 (November 2013): 1981–83. https://doi.org/10.1038/mt.2013.227.Full Text Link to Item
-
Yang, Shicheng, Gary E. Archer, Catherine E. Flores, Duane A. Mitchell, and John H. Sampson. “A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.” Cancer Immunol Immunother 62, no. 11 (November 2013): 1649–62. https://doi.org/10.1007/s00262-013-1464-0.Full Text Link to Item
-
Batich, Kristen A., E. William St Clair, Roger E. McLendon, and John H. Sampson. “Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease.” J Clin Neurosci 20, no. 10 (October 2013): 1445–48. https://doi.org/10.1016/j.jocn.2013.01.009.Full Text Link to Item
-
Choi, Bryan D., Patrick C. Gedeon, Chien-Tsun Kuan, Luis Sanchez-Perez, Gary E. Archer, Darell D. Bigner, and John H. Sampson. “Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.” J Immunol Methods 395, no. 1–2 (September 30, 2013): 14–20. https://doi.org/10.1016/j.jim.2013.06.003.Full Text Link to Item
-
Choi, Bryan D., Patrick C. Gedeon, James E. Herndon, Gary E. Archer, Elizabeth A. Reap, Luis Sanchez-Perez, Duane A. Mitchell, Darell D. Bigner, and John H. Sampson. “Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.” Cancer Immunol Res 1, no. 3 (September 2013): 163. https://doi.org/10.1158/2326-6066.CIR-13-0049.Full Text Link to Item
-
Gururangan, S., G. A. Grant, T. Driscoll, G. Archer, E. J. Sayour, J. E. Herndon, H. S. Friedman, et al. “ADOPTIVE LYMPHOCYTE THERAPY (ALT) PLUS DENDRITIC CELL VACCINATION (DCV) AFTER MYELOABLATIVE (MA) OR NON-MYELOABLATIVE (NMA) CONDITIONING IN PATIENTS WITH RECURRENT CENTRAL PNET (C-PNET).” Pediatric Blood & Cancer 60 (September 1, 2013): 13–13.Link to Item
-
Babu, Ranjith, Jeffrey Hatef, Roger E. McLendon, Thomas J. Cummings, John H. Sampson, Allan H. Friedman, and Cory Adamson. “Clinicopathological characteristics and treatment of rhabdoid glioblastoma.” J Neurosurg 119, no. 2 (August 2013): 412–19. https://doi.org/10.3171/2013.3.JNS121773.Full Text Link to Item
-
Sampson, J. H., A. Desjardins, K. B. Peters, T. Ranjan, G. Vlahovic, D. Lally-Goss, S. Threatt, et al. “107 Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” Neurosurgery 60 Suppl 1 (August 2013): 155. https://doi.org/10.1227/01.neu.0000432699.02392.a4.Full Text Link to Item
-
Cabrera, Alvin R., Kyle C. Cuneo, Annick Desjardins, John H. Sampson, Frances McSherry, James E. Herndon, Katherine B. Peters, et al. “Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.” Int J Radiat Oncol Biol Phys 86, no. 5 (August 1, 2013): 873–79. https://doi.org/10.1016/j.ijrobp.2013.04.029.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, Duane A. Mitchell, Laura A. Johnson, John H. Sampson, and Darell D. Bigner. “Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.” Future Oncol 9, no. 7 (July 2013): 977–90. https://doi.org/10.2217/fon.13.47.Full Text Link to Item
-
Dannull, Jens, N Rebecca Haley, Gary Archer, Smita Nair, David Boczkowski, Mark Harper, Nicole De Rosa, et al. “Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.” J Clin Invest 123, no. 7 (July 2013): 3135–45. https://doi.org/10.1172/JCI67544.Full Text Link to Item
-
Gedeon, Patrick C., Bryan D. Choi, Tiffany R. Hodges, Duane A. Mitchell, Darell D. Bigner, and John H. Sampson. “An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.” Expert Rev Clin Pharmacol 6, no. 4 (July 2013): 375–86. https://doi.org/10.1586/17512433.2013.811806.Full Text Link to Item
-
Kirkpatrick, John P., Fang-Fang Yin, and John H. Sampson. “Radiotherapy and radiosurgery for tumors of the central nervous system.” Surg Oncol Clin N Am 22, no. 3 (July 2013): 445–61. https://doi.org/10.1016/j.soc.2013.02.008.Full Text Link to Item
-
Hodges, Tiffany R., Bryan D. Choi, Darell D. Bigner, Hai Yan, and John H. Sampson. “Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.” J Neurosurg 118, no. 6 (June 2013): 1176–80. https://doi.org/10.3171/2013.3.JNS122282.Full Text Link to Item
-
Nonaka, Yoichi, Takanori Fukushima, Kentaro Watanabe, Allan H. Friedman, John H. Sampson, John T. Mcelveen, Calhoun D. Cunningham, and Ali R. Zomorodi. “Contemporary surgical management of vestibular schwannomas: analysis of complications and lessons learned over the past decade.” Neurosurgery 72, no. 2 Suppl Operative (June 2013): ons103–15. https://doi.org/10.1227/NEU.0b013e3182752b05.Full Text Link to Item
-
Reardon, David A., Kai W. Wucherpfennig, Gordon Freeman, Catherine J. Wu, E Antonio Chiocca, Patrick Y. Wen, William T. Curry, et al. “An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.” Expert Rev Vaccines 12, no. 6 (June 2013): 597–615. https://doi.org/10.1586/erv.13.41.Full Text Link to Item
-
Sanchez-Perez, Luis, Bryan D. Choi, Elizabeth A. Reap, Elias J. Sayour, Pamela Norberg, Robert J. Schmittling, Gerald E. Archer, et al. “BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.” Cancer Immunol Immunother 62, no. 6 (June 2013): 983–87. https://doi.org/10.1007/s00262-013-1405-y.Full Text Link to Item
-
Chandramohan, V., D. A. Mitchell, M. Gromeier, J. H. Sampson, and D. D. Bigner. “Current immunotherapeutic targets in gliomas,” May 1, 2013, 287–305.
-
Mehta, Ankit I., Adam M. Brufsky, and John H. Sampson. “Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.” Cancer Treat Rev 39, no. 3 (May 2013): 261–69. https://doi.org/10.1016/j.ctrv.2012.05.006.Full Text Link to Item
-
Choi, Bryan D., Ira Pastan, Darell D. Bigner, and John H. Sampson. “A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.” Oncoimmunology 2, no. 4 (April 1, 2013): e23639. https://doi.org/10.4161/onci.23639.Full Text Link to Item
-
Gedeon, Patrick C., Bryan D. Choi, John H. Sampson, and Darell D. Bigner. “Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.” Drugs Future 38, no. 3 (March 2013): 147–55. https://doi.org/10.1358/dof.2013.038.03.1933992.Full Text Link to Item
-
Mehta, Ankit I., Ranjith Babu, Richa Sharma, Isaac O. Karikari, Betsy H. Grunch, Timothy R. Owens, Vijay J. Agarwal, et al. “Thickness of subcutaneous fat as a risk factor for infection in cervical spine fusion surgery.” J Bone Joint Surg Am 95, no. 4 (February 20, 2013): 323–28. https://doi.org/10.2106/JBJS.L.00225.Full Text Link to Item
-
Choi, Bryan D., Chien-Tsun Kuan, Mingqing Cai, Gary E. Archer, Duane A. Mitchell, Patrick C. Gedeon, Luis Sanchez-Perez, Ira Pastan, Darell D. Bigner, and John H. Sampson. “Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.” Proc Natl Acad Sci U S A 110, no. 1 (January 2, 2013): 270–75. https://doi.org/10.1073/pnas.1219817110.Full Text Link to Item
-
Sanchez-Perez, Luis A., Bryan D. Choi, Gary E. Archer, Xiuyu Cui, Catherine Flores, Laura A. Johnson, Robert J. Schmittling, et al. “Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.” Plos One 8, no. 3 (2013): e59082. https://doi.org/10.1371/journal.pone.0059082.Full Text Open Access Copy Link to Item
-
Zomorodi, Ali, James E. Herndon, and John H. Sampson. “Subarachnoid hemorrhage trials.” J Neurosurg 118, no. 1 (January 2013): 1–2. https://doi.org/10.3171/2012.5.JNS12730.Full Text Link to Item
-
Ajay, Divya, Luis Sanchez-Perez, Bryan D. Choi, Gabriel De Leon, and John H. Sampson. “Immunotherapy with tumor vaccines for the treatment of malignant gliomas.” Curr Drug Discov Technol 9, no. 4 (December 2012): 237–55. https://doi.org/10.2174/157016312803305933.Full Text Link to Item
-
Mehta, Ankit I., Bryan D. Choi, Divya Ajay, Raghu Raghavan, Martin Brady, Allan H. Friedman, Ira Pastan, Darell D. Bigner, and John H. Sampson. “Convection enhanced delivery of macromolecules for brain tumors.” Curr Drug Discov Technol 9, no. 4 (December 2012): 305–10. https://doi.org/10.2174/157016312803305951.Full Text Link to Item
-
Sampson, John H. “Editorial: Convection-enhanced delivery.” J Neurosurg 117, no. 6 (December 2012): 1126–27. https://doi.org/10.3171/2012.1.JNS12208.Full Text Link to Item
-
Choi, Bryan D., Peter E. Fecci, and John H. Sampson. “Regulatory T cells move in when gliomas say "I Do".” Clin Cancer Res 18, no. 22 (November 15, 2012): 6086–88. https://doi.org/10.1158/1078-0432.CCR-12-2801.Full Text Link to Item
-
Mehta, V Ankit I., and John H. Sampson. “The limitations of imaging response criteria.” Lancet Oncol 13, no. 11 (November 2012): 1064–65. https://doi.org/10.1016/S1470-2045(12)70458-8.Full Text Link to Item
-
Reitman, Zachary J., Bryan D. Choi, Ivan Spasojevic, Darell D. Bigner, John H. Sampson, and Hai Yan. “Enzyme redesign guided by cancer-derived IDH1 mutations.” Nat Chem Biol 8, no. 11 (November 2012): 887–89. https://doi.org/10.1038/nchembio.1065.Full Text Link to Item
-
Reardon, D. A., J. E. Herndon, K. B. Peters, A. Desjardins, A. Coan, E. Lou, A. L. Sumrall, et al. “Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.” Br J Cancer 107, no. 9 (October 23, 2012): 1481–87. https://doi.org/10.1038/bjc.2012.415.Full Text Open Access Copy Link to Item
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sith Sathornsumetee, Stevie Threatt, John H. Sampson, et al. “Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.” J Neurooncol 108, no. 3 (July 2012): 499–506. https://doi.org/10.1007/s11060-012-0848-x.Full Text Link to Item
-
Cabrera, Alvin R., Kyle C. Cuneo, James J. Vredenburgh, John H. Sampson, and John P. Kirkpatrick. “Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.” J Natl Compr Canc Netw 10, no. 6 (June 1, 2012): 695–99. https://doi.org/10.6004/jnccn.2012.0072.Full Text Link to Item
-
Cuneo, K. C., T. M. Zagar, D. M. Brizel, D. S. Yoo, J. K. Hoang, Z. Chang, Z. Wang, et al. “Stereotactic radiotherapy for malignancies involving the trigeminal and facial nerves.” Technol Cancer Res Treat 11, no. 3 (June 2012): 221–28. https://doi.org/10.7785/tcrt.2012.500290.Full Text Link to Item
-
Sampson, John H., and Jenny K. Hoang. “Resection and survival.” J Neurosurg 116, no. 6 (June 2012): 1169–70. https://doi.org/10.3171/2011.10.JNS111437.Full Text Link to Item
-
Choi, Bryan D., Ankit I. Mehta, Kristen A. Batich, Allan H. Friedman, and John H. Sampson. “The use of motor mapping to aid resection of eloquent gliomas.” Neurosurg Clin N Am 23, no. 2 (April 2012): 215–vii. https://doi.org/10.1016/j.nec.2012.01.013.Full Text Link to Item
-
Cuneo, Kyle C., James J. Vredenburgh, John H. Sampson, David A. Reardon, Annick Desjardins, Katherine B. Peters, Henry S. Friedman, Christopher G. Willett, and John P. Kirkpatrick. “Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.” Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): 2018–24. https://doi.org/10.1016/j.ijrobp.2010.12.074.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, et al. “Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.” J Neurooncol 107, no. 1 (March 2012): 155–64. https://doi.org/10.1007/s11060-011-0722-2.Full Text Link to Item
-
Sampson, John H., Carlos A. Bagley, and Benjamin S. Carson. “Disparities in care.” J Neurosurg 116, no. 2 (February 2012): 280–82. https://doi.org/10.3171/2011.5.JNS11410.Full Text Link to Item
-
Sampson, John H., James E. Herndon, Roger E. McLendon, Vic Hasselblad, Anthony L. Asher, Matthew J. McGirt, and Eric D. Peterson. “Clinical data simplified.” J Neurosurg 116, no. 2 (February 2012): 346–48. https://doi.org/10.3171/2011.5.JNS11279.Full Text Link to Item
-
Desjardins, Annick, and John H. Sampson. “Avastin: more questions than answers. .” J Neurosurg 116, no. 2 (February 2012): 336–40. https://doi.org/10.3171/2011.8.JNS111107.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, John H. Sampson, Ira Pastan, and Darell D. Bigner. “Toxin-based targeted therapy for malignant brain tumors.” Clin Dev Immunol 2012 (2012): 480429. https://doi.org/10.1155/2012/480429.Full Text Open Access Copy Link to Item
-
Reardon, David A., Andrew D. Norden, Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, John H. Sampson, et al. “Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.” J Neurooncol 106, no. 2 (January 2012): 409–15. https://doi.org/10.1007/s11060-011-0687-1.Full Text Link to Item
-
Sampson, John H., Robert J. Schmittling, Gary E. Archer, Kendra L. Congdon, Smita K. Nair, Elizabeth A. Reap, Annick Desjardins, et al. “A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.” Plos One 7, no. 2 (2012): e31046. https://doi.org/10.1371/journal.pone.0031046.Full Text Open Access Copy Link to Item
-
Vogelbaum, Michael A., Sarah Jost, Manish K. Aghi, Amy B. Heimberger, John H. Sampson, Patrick Y. Wen, David R. Macdonald, Martin J. Van den Bent, and Susan M. Chang. “Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.” Neurosurgery 70, no. 1 (January 2012): 234–43. https://doi.org/10.1227/NEU.0b013e318223f5a7.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, John P. Kirkpatrick, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, et al. “Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.” Int J Radiat Oncol Biol Phys 82, no. 1 (January 1, 2012): 58–66. https://doi.org/10.1016/j.ijrobp.2010.08.058.Full Text Link to Item
-
Mehta, A. I., G. A. Grant, L. Gray, and J. H. Sampson. “Radiographic progression of a Chiari I malformation after minor head trauma: Final increment of obstruction to create pathophysiology.” Journal of Surgical Radiology 2, no. 3 (December 1, 2011): 290–93.
-
Reardon, David A., Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” Cancer 117, no. 23 (December 1, 2011): 5351–58. https://doi.org/10.1002/cncr.26188.Full Text Link to Item
-
Mitchell, Duane A., Gary E. Archer, Henry S. Friedman, James E. Herndon, Darell D. Bigner, and John H. Sampson. “DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS IN GLIOBLASTOMA.” Neuro Oncology 13 (November 1, 2011): 39–39.Link to Item
-
Buonerba, Carlo, Giuseppe Di Lorenzo, Alfredo Marinelli, Piera Federico, Giovannella Palmieri, Martina Imbimbo, Pio Conti, Gianfranco Peluso, Sabino De Placido, and John H. Sampson. “A comprehensive outlook on intracerebral therapy of malignant gliomas.” Crit Rev Oncol Hematol 80, no. 1 (October 2011): 54–68. https://doi.org/10.1016/j.critrevonc.2010.09.001.Full Text Link to Item
-
Lou, Emil, Scott Turner, Ashley Sumrall, David A. Reardon, Annick Desjardins, Katherine B. Peters, John H. Sampson, Henry S. Friedman, and James J. Vredenburgh. “Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.” J Clin Oncol 29, no. 28 (October 1, 2011): e739–42. https://doi.org/10.1200/JCO.2011.36.1865.Full Text Link to Item
-
Mitchell, Duane A., Xiuyu Cui, Robert J. Schmittling, Luis Sanchez-Perez, David J. Snyder, Kendra L. Congdon, Gary E. Archer, et al. “Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.” Blood 118, no. 11 (September 15, 2011): 3003–12. https://doi.org/10.1182/blood-2011-02-334565.Full Text Link to Item
-
Sampson, John H., Raghu Raghavan, Martin Brady, Allan H. Friedman, and Darell Bigner. “Convection-enhanced delivery.” J Neurosurg 115, no. 3 (September 2011): 463–64. https://doi.org/10.3171/2010.11.JNS101801.Full Text Link to Item
-
Sampson, John H., Martin Brady, Raghu Raghavan, Ankit I. Mehta, Allan H. Friedman, David A. Reardon, Neil A. Petry, et al. “Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.” Neurosurgery 69, no. 3 (September 2011): 668–76. https://doi.org/10.1227/NEU.0b013e3182181ba8.Full Text Link to Item
-
Mehta, A. I., O. Persson, J. E. Herndon, G. E. Archer, R. McLendon, A. B. Heimberger, D. A. Mitchell, D. D. Bigner, and J. H. Sampson. “Reply to M.S. Lesniak.” Journal of Clinical Oncology 29, no. 22 (August 1, 2011): 3105–6. https://doi.org/10.1200/JCO.2011.35.0256.Full Text
-
Sampson, John H., James E. Herndon, Allan H. Friedman, and Amy P. Abernethy. “Epidemiology.” J Neurosurg 115, no. 2 (August 2011): 256–57. https://doi.org/10.3171/2011.1.JNS102066.Full Text Link to Item
-
Sampson, John H., Thomas J. Kaminski, and Kevin A. Schulman. “Our failure to advance new treatments for glioma to market.” J Neurosurg 115, no. 2 (August 2011): 245–47. https://doi.org/10.3171/2010.11.JNS101436.Full Text Link to Item
-
Sampson, John H., and Duane A. Mitchell. “Is cytomegalovirus a therapeutic target in glioblastoma?” Clin Cancer Res 17, no. 14 (July 15, 2011): 4619–21. https://doi.org/10.1158/1078-0432.CCR-11-0992.Full Text Link to Item
-
Choi, Bryan D., Mingqing Cai, Darell D. Bigner, Ankit I. Mehta, Chien-Tsun Kuan, and John H. Sampson. “Bispecific antibodies engage T cells for antitumor immunotherapy.” Expert Opin Biol Ther 11, no. 7 (July 2011): 843–53. https://doi.org/10.1517/14712598.2011.572874.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, John P. Kirkpatrick, et al. “The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.” Clin Cancer Res 17, no. 12 (June 15, 2011): 4119–24. https://doi.org/10.1158/1078-0432.CCR-11-0120.Full Text Link to Item
-
Heimberger, A. B., D. D. Bigner, J. E. Herndon, and J. H. Sampson. “Reply to M.C. Chamberlain.” Journal of Clinical Oncology 29, no. 17 (June 10, 2011). https://doi.org/10.1200/JCO.2010.34.1453.Full Text
-
Reardon, David A., Annick Desjardins, Katherine Peters, Sridharan Gururangan, John Sampson, Jeremy N. Rich, Roger McLendon, et al. “Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” J Neurooncol 103, no. 2 (June 2011): 371–79. https://doi.org/10.1007/s11060-010-0403-6.Full Text Link to Item
-
Cuneo, K. C., A. R. Cabrera, J. H. Sampson, K. J. Allen, J. J. Vredenburgh, K. Peters, Z. Chang, et al. “Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2082–2082. https://doi.org/10.1200/jco.2011.29.15_suppl.2082.Full Text
-
Sampson, John H., and James E. Herndon. “Resection of vestibular schwannomas.” J Neurosurg 114, no. 5 (May 2011): 1216–17. https://doi.org/10.3171/2010.8.JNS10765.Full Text Link to Item
-
Reardon, David A., Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.” J Natl Compr Canc Netw 9, no. 4 (April 2011): 414–27. https://doi.org/10.6004/jnccn.2011.0038.Full Text Link to Item
-
De Leon, Gabriel, Duane Mitchell, and John Sampson. “A promising cancer vaccine.” Future Oncol 7, no. 3 (March 2011): 331–34. https://doi.org/10.2217/fon.11.17.Full Text Link to Item
-
Mehta, Ankit I., Bryan D. Choi, Raghu Raghavan, Martin Brady, Allan H. Friedman, Darell D. Bigner, Ira Pastan, and John H. Sampson. “Imaging of convection enhanced delivery of toxins in humans.” Toxins (Basel) 3, no. 3 (March 2011): 201–6. https://doi.org/10.3390/toxins3030201.Full Text Link to Item
-
Mehta, Ankit I., Charles W. Kanaly, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “Monitoring radiographic brain tumor progression.” Toxins (Basel) 3, no. 3 (March 2011): 191–200. https://doi.org/10.3390/toxins3030191.Full Text Link to Item
-
Reardon, David A., Evanthia Galanis, John F. DeGroot, Timothy F. Cloughesy, Jeffrey S. Wefel, Kathleen R. Lamborn, Andrew B. Lassman, et al. “Clinical trial end points for high-grade glioma: the evolving landscape.” Neuro Oncol 13, no. 3 (March 2011): 353–61. https://doi.org/10.1093/neuonc/noq203.Full Text Link to Item
-
Sampson, John H. “Low-grade glioma.” J Neurosurg 114, no. 3 (March 2011): 563–64. https://doi.org/10.3171/2010.1.JNS091940.Full Text Link to Item
-
Sampson, John H., Kenneth D. Aldape, Gary E. Archer, April Coan, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, et al. “Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.” Neuro Oncol 13, no. 3 (March 2011): 324–33. https://doi.org/10.1093/neuonc/noq157.Full Text Link to Item
-
Kanaly, Charles W., Dale Ding, Ankit I. Mehta, Anthony F. Waller, Ian Crocker, Annick Desjardins, David A. Reardon, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “A novel method for volumetric MRI response assessment of enhancing brain tumors.” Plos One 6, no. 1 (January 26, 2011): e16031. https://doi.org/10.1371/journal.pone.0016031.Full Text Link to Item
-
Heimberger, Amy B., and John H. Sampson. “Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?” Neuro Oncol 13, no. 1 (January 2011): 3–13. https://doi.org/10.1093/neuonc/noq169.Full Text Link to Item
-
Mueller, Sabine, Mei-Yin Polley, Benjamin Lee, Sandeep Kunwar, Christoph Pedain, Eva Wembacher-Schröder, Stephan Mittermeyer, et al. “Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.” J Neurooncol 101, no. 2 (January 2011): 267–77. https://doi.org/10.1007/s11060-010-0255-0.Full Text Link to Item
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine Peters, Sridharan Gururangan, John H. Sampson, Jennifer Marcello, et al. “Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.” J Neurooncol 101, no. 1 (January 2011): 57–66. https://doi.org/10.1007/s11060-010-0217-6.Full Text Link to Item
-
Sampson, John H., Amy B. Heimberger, Gary E. Archer, Kenneth D. Aldape, Allan H. Friedman, Henry S. Friedman, Mark R. Gilbert, et al. “Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.” J Clin Oncol 28, no. 31 (November 1, 2010): 4722–29. https://doi.org/10.1200/JCO.2010.28.6963.Full Text Link to Item
-
Ding, Dale, Charles W. Kanaly, Thomas J. Cummings, James E. Herndon, Raghu Raghavan, and John H. Sampson. “Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.” Neurol Res 32, no. 8 (October 2010): 810–15. https://doi.org/10.1179/174367509X12581069052090.Full Text Link to Item
-
Kunwar, Sandeep, Susan Chang, Manfred Westphal, Michael Vogelbaum, John Sampson, Gene Barnett, Mark Shaffrey, et al. “Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.” Neuro Oncol 12, no. 8 (August 2010): 871–81. https://doi.org/10.1093/neuonc/nop054.Full Text Link to Item
-
Sampson, John H., Gary Archer, Christoph Pedain, Eva Wembacher-Schröder, Manfred Westphal, Sandeep Kunwar, Michael A. Vogelbaum, et al. “Poor drug distribution as a possible explanation for the results of the PRECISE trial.” J Neurosurg 113, no. 2 (August 2010): 301–9. https://doi.org/10.3171/2009.11.JNS091052.Full Text Link to Item
-
Aliabadi, Hamidreza, James J. Vredenburgh, Richard G. Everson, Annick Desjardins, Henry S. Friedman, Roger E. McLendon, Debara L. Tucci, and John H. Sampson. “Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.” J Neurooncol 98, no. 3 (July 2010): 427–30. https://doi.org/10.1007/s11060-009-0091-2.Full Text Link to Item
-
Johnson, Laura A., and John H. Sampson. “Immunotherapy approaches for malignant glioma from 2007 to 2009.” Curr Neurol Neurosci Rep 10, no. 4 (July 2010): 259–66. https://doi.org/10.1007/s11910-010-0111-9.Full Text Link to Item
-
Chong, Gabriel T., Srinivasan Mukundan, John P. Kirkpatrick, Ali Zomorodi, John H. Sampson, and M Tariq Bhatti. “Stereotactic radiosurgery in the treatment of a dural carotid-cavernous fistula.” J Neuroophthalmol 30, no. 2 (June 2010): 138–44. https://doi.org/10.1097/WNO.0b013e3181ceb3e3.Full Text Link to Item
-
Lai, R., L. D. Recht, D. A. Reardon, N. Paleologos, M. D. Groves, M. R. Rosenfeld, S. Meech, T. A. Davis, D. Pavlov, and J. H. Sampson. “Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2014–2014. https://doi.org/10.1200/jco.2010.28.15_suppl.2014.Full Text
-
Ding, D., C. W. Kanaly, D. D. Bigner, T. J. Cummings, J. E. Herndon, I. Pastan, R. Raghavan, and J. H. Sampson. “Erratum: Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1 (Journal of Neuro-Oncology DOI 10.1007/s11060-009-0046-7).” Journal of Neuro Oncology 98, no. 1 (May 1, 2010): 9. https://doi.org/10.1007/s11060-010-0183-z.Full Text
-
Ding, Dale, Charles W. Kanaly, Darrell D. Bigner, Thomas J. Cummings, James E. Herndon, Ira Pastan, Raghu Raghavan, and John H. Sampson. “Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.” J Neurooncol 98, no. 1 (May 2010): 1–7. https://doi.org/10.1007/s11060-009-0046-7.Full Text Link to Item
-
Ding, D., C. W. Kanaly, M. L. Brady, S. Mittermeyer, R. Raghavan, and J. H. Sampson. “Convection-enhanced drug delivery to the brain.” Neuromethods 45 (January 15, 2010): 291–318. https://doi.org/10.1007/978-1-60761-529-3_15.Full Text
-
Humphries, William, Jun Wei, John H. Sampson, and Amy B. Heimberger. “The role of tregs in glioma-mediated immunosuppression: potential target for intervention.” Neurosurg Clin N Am 21, no. 1 (January 2010): 125–37. https://doi.org/10.1016/j.nec.2009.08.012.Full Text Link to Item
-
Kanaly, Charles W., Dale Ding, Amy B. Heimberger, and John H. Sampson. “Clinical applications of a peptide-based vaccine for glioblastoma.” Neurosurg Clin N Am 21, no. 1 (January 2010): 95–109. https://doi.org/10.1016/j.nec.2009.09.001.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, James E. Herndon, Jennifer Marcello, et al. “Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.” J Neurooncol 96, no. 2 (January 2010): 219–30. https://doi.org/10.1007/s11060-009-9950-0.Full Text Link to Item
-
Reardon, D. A., A. Desjardins, J. J. Vredenburgh, S. Gururangan, J. H. Sampson, S. Sathornsumetee, R. E. McLendon, et al. “Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.” Br J Cancer 101, no. 12 (December 15, 2009): 1986–94. https://doi.org/10.1038/sj.bjc.6605412.Full Text Open Access Copy Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, John H. Sampson, Roger E. McLendon, James E. Herndon, and Henry S. Friedman. “Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.” J Neurooncol 95, no. 3 (December 2009): 393–400. https://doi.org/10.1007/s11060-009-9937-x.Full Text Link to Item
-
Choi, Bryan D., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, Roger E. McLendon, Darell D. Bigner, and John H. Sampson. “EGFRvIII-targeted vaccination therapy of malignant glioma.” Brain Pathol 19, no. 4 (October 2009): 713–23. https://doi.org/10.1111/j.1750-3639.2009.00318.x.Full Text Link to Item
-
Sampson, John H., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, James E. Herndon, Denise Lally-Goss, Sharon McGehee-Norman, et al. “An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.” Mol Cancer Ther 8, no. 10 (October 2009): 2773–79. https://doi.org/10.1158/1535-7163.MCT-09-0124.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.” Neuro Oncol 11, no. 5 (October 2009): 556–61. https://doi.org/10.1215/15228517-2009-007.Full Text Link to Item
-
Valles, Francisco, Massimo S. Fiandaca, John Bringas, Peter Dickinson, Richard LeCouteur, Robert Higgins, Mitchel Berger, John Forsayeth, and Krystof S. Bankiewicz. “Anatomic compression caused by high-volume convection-enhanced delivery to the brain.” Neurosurgery 65, no. 3 (September 2009): 579–85. https://doi.org/10.1227/01.NEU.0000350229.77462.2F.Full Text Link to Item
-
Heimberger, Amy B., and John H. Sampson. “The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.” Expert Opin Biol Ther 9, no. 8 (August 2009): 1087–98. https://doi.org/10.1517/14712590903124346.Full Text Link to Item
-
Boskovitz, Abraham, Roger E. McLendon, Tatsunori Okamura, John H. Sampson, Darell D. Bigner, and Michael R. Zalutsky. “Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.” Nucl Med Biol 36, no. 6 (August 2009): 659–69. https://doi.org/10.1016/j.nucmedbio.2009.04.003.Full Text Link to Item
-
Wiemels, Joseph L., David Wilson, Chirag Patil, Joseph Patoka, Lucie McCoy, Terri Rice, Judith Schwartzbaum, et al. “IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.” Int J Cancer 125, no. 3 (August 1, 2009): 680–87. https://doi.org/10.1002/ijc.24369.Full Text Link to Item
-
Mitchell, Duane A., and John H. Sampson. “Toward effective immunotherapy for the treatment of malignant brain tumors.” Neurotherapeutics 6, no. 3 (July 2009): 527–38. https://doi.org/10.1016/j.nurt.2009.04.003.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, and Henry S. Friedman. “Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.” Cancer 115, no. 13 (July 1, 2009): 2964–70. https://doi.org/10.1002/cncr.24336.Full Text Link to Item
-
Chino, Junzo P., John H. Sampson, Debara L. Tucci, David M. Brizel, and John P. Kirkpatrick. “Paraganglioma of the head and neck: long-term local control with radiotherapy.” Am J Clin Oncol 32, no. 3 (June 2009): 304–7. https://doi.org/10.1097/COC.0b013e318187dd94.Full Text Link to Item
-
Akazawa, Toshimasa, Shawn G. Kwatra, Laura E. Goldsmith, Mark D. Richardson, Elizabeth A. Cox, John H. Sampson, and Madan M. Kwatra. “A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.” J Neurochem 109, no. 4 (May 2009): 1079–86. https://doi.org/10.1111/j.1471-4159.2009.06032.x.Full Text Link to Item
-
Graner, Michael W., Oscar Alzate, Angelika M. Dechkovskaia, Jack D. Keene, John H. Sampson, Duane A. Mitchell, and Darell D. Bigner. “Proteomic and immunologic analyses of brain tumor exosomes.” Faseb J 23, no. 5 (May 2009): 1541–57. https://doi.org/10.1096/fj.08-122184.Full Text Link to Item
-
Archer, Gary E., Amy B. Heimberger, Darell D. Bigner, Tom Davis, Henry S. Friedman, Tibor Keler, Roger E. McLendon, et al. “INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRVIII-POSITIVE GBM.” Neuro Oncology 11, no. 2 (April 1, 2009): 224–224.Link to Item
-
Gromeier, Matthias, Valentina Neplioueva, Neel Makherjee, Melinda Merrill, and John H. Sampson. “THE RNA-BINDING PROTEIN 76 CONTROLS GENE EXPRESSION IN GBM.” Neuro Oncology 11, no. 2 (April 1, 2009): 221–221.Link to Item
-
Nelson, John W., David S. Yoo, John H. Sampson, Robert E. Isaacs, Nicole A. Larrier, Lawrence B. Marks, Fang-Fang Yin, Q Jackie Wu, Zhiheng Wang, and John P. Kirkpatrick. “Stereotactic body radiotherapy for lesions of the spine and paraspinal regions.” Int J Radiat Oncol Biol Phys 73, no. 5 (April 1, 2009): 1369–75. https://doi.org/10.1016/j.ijrobp.2008.06.1949.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.” J Clin Oncol 27, no. 8 (March 10, 2009): 1262–67. https://doi.org/10.1200/JCO.2008.18.8417.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, James Carter, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, et al. “Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.” Clin Cancer Res 15, no. 3 (February 1, 2009): 1064–68. https://doi.org/10.1158/1078-0432.CCR-08-2130.Full Text Link to Item
-
Heimberger, Amy B., Ling-Yuan Kong, Mohamed Abou-Ghazal, Chantal Reina-Ortiz, David S. Yang, Jun Wei, Wei Qiao, et al. “The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.” Clin Neurosurg 56 (2009): 98–106.Link to Item
-
Schmittling, Robert J., Gary E. Archer, Duane A. Mitchell, Amy Heimberger, Charles Pegram, James E. Herndon, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.” J Immunol Methods 339, no. 1 (November 30, 2008): 74–81. https://doi.org/10.1016/j.jim.2008.08.004.Full Text Link to Item
-
Desjardins, Annick, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, et al. “Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.” Clin Cancer Res 14, no. 21 (November 1, 2008): 7068–73. https://doi.org/10.1158/1078-0432.CCR-08-0260.Full Text Link to Item
-
Varenika, Vanja, Peter Dickinson, John Bringas, Richard LeCouteur, Robert Higgins, John Park, Massimo Fiandaca, Mitchel Berger, John Sampson, and Krystof Bankiewicz. “Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery.” J Neurosurg 109, no. 5 (November 2008): 874–80. https://doi.org/10.3171/JNS/2008/109/11/0874.Full Text Link to Item
-
Sampson, John H., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, and Darell D. Bigner. “Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.” Semin Immunol 20, no. 5 (October 2008): 267–75. https://doi.org/10.1016/j.smim.2008.04.001.Full Text Link to Item
-
Kong, Ling-Yuan, Mohamed K. Abou-Ghazal, Jun Wei, Arup Chakraborty, Wei Sun, Wei Qiao, Gregory N. Fuller, et al. “A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.” Clin Cancer Res 14, no. 18 (September 15, 2008): 5759–68. https://doi.org/10.1158/1078-0432.CCR-08-0377.Full Text Link to Item
-
Choi, Jonathan D., Ciaran J. Powers, James J. Vredenburgh, Allan H. Friedman, and John H. Sampson. “Cryptococcal meningitis in patients with glioma: a report of two cases.” J Neurooncol 89, no. 1 (August 2008): 51–53. https://doi.org/10.1007/s11060-008-9581-x.Full Text Link to Item
-
Sampson, John H., Gamal Akabani, Gerald E. Archer, Mitchel S. Berger, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, et al. “Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.” Neuro Oncol 10, no. 3 (June 2008): 320–29. https://doi.org/10.1215/15228517-2008-012.Full Text Link to Item
-
Vega, Eleanor A., Michael W. Graner, and John H. Sampson. “Combating immunosuppression in glioma.” Future Oncol 4, no. 3 (June 2008): 433–42. https://doi.org/10.2217/14796694.4.3.433.Full Text Link to Item
-
Mitchell, Duane A., Isaac Karikari, Xiuyu Cui, Weihua Xie, Robert Schmittling, and John H. Sampson. “Selective modification of antigen-specific T cells by RNA electroporation.” Hum Gene Ther 19, no. 5 (May 2008): 511–21. https://doi.org/10.1089/hum.2007.115.Full Text Link to Item
-
Everson, Richard G., Michael W. Graner, Matthias Gromeier, James J. Vredenburgh, Annick Desjardins, David A. Reardon, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.” Expert Rev Anticancer Ther 8, no. 5 (May 2008): 717–32. https://doi.org/10.1586/14737140.8.5.717.Full Text Link to Item
-
Mitchell, Duane A., Peter E. Fecci, and John H. Sampson. “Immunotherapy of malignant brain tumors.” Immunol Rev 222 (April 2008): 70–100. https://doi.org/10.1111/j.1600-065X.2008.00603.x.Full Text Link to Item
-
Selznick, Lee A., Mohammed F. Shamji, Peter Fecci, Matthias Gromeier, Allan H. Friedman, and John Sampson. “Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.” Neurosurg Rev 31, no. 2 (April 2008): 141–55. https://doi.org/10.1007/s10143-008-0121-0.Full Text Link to Item
-
Heimberger, Amy B., Wei Sun, S Farzana Hussain, Mahua Dey, Lamonne Crutcher, Ken Aldape, Mark Gilbert, et al. “Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.” Neuro Oncol 10, no. 1 (February 2008): 98–103. https://doi.org/10.1215/15228517-2007-046.Full Text Link to Item
-
Mitchell, Duane A., Weihua Xie, Robert Schmittling, Chris Learn, Allan Friedman, Roger E. McLendon, and John H. Sampson. “Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.” Neuro Oncol 10, no. 1 (February 2008): 10–18. https://doi.org/10.1215/15228517-2007-035.Full Text Link to Item
-
Grossi, Peter M., Michael J. Ellis, Thomas J. Cummings, Linda L. Gray, Takanori Fukushima, and John H. Sampson. “Cholesterol granuloma of the lateral ventricle. Case report.” J Neurosurg 108, no. 2 (February 2008): 357–60. https://doi.org/10.3171/JNS/2008/108/2/0357.Full Text Link to Item
-
Ochiai, Hidenobu, Gary E. Archer, James E. Herndon, Chien-Tsun Kuan, Duane A. Mitchell, Darell D. Bigner, Ira H. Pastan, and John H. Sampson. “EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.” Cancer Immunol Immunother 57, no. 1 (January 2008): 115–21. https://doi.org/10.1007/s00262-007-0363-7.Full Text Link to Item
-
Vogelbaum, Michael A., John H. Sampson, Sandeep Kunwar, Susan M. Chang, Mark Shaffrey, Anthony L. Asher, Frederick F. Lang, et al. “Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.” Neurosurgery 61, no. 5 (November 2007): 1031–37. https://doi.org/10.1227/01.neu.0000303199.77370.9e.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.” J Clin Oncol 25, no. 30 (October 20, 2007): 4722–29. https://doi.org/10.1200/JCO.2007.12.2440.Full Text Link to Item
-
Sampson, John H., Raghu Raghavan, Martin L. Brady, James M. Provenzale, James E. Herndon, David Croteau, Allan H. Friedman, et al. “Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.” Neuro Oncol 9, no. 3 (July 2007): 343–53. https://doi.org/10.1215/15228517-2007-007.Full Text Link to Item
-
Desjardins, Annick, Jennifer A. Quinn, James J. Vredenburgh, Sith Sathornsumetee, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.” J Neurooncol 83, no. 1 (May 2007): 53–60. https://doi.org/10.1007/s11060-006-9302-2.Full Text Link to Item
-
Everson, Richard G., Mathias Gromeier, and John H. Sampson. “Viruses in the treatment of malignant glioma.” Expert Rev Neurother 7, no. 4 (April 2007): 321–24. https://doi.org/10.1586/14737175.7.4.321.Full Text Link to Item
-
Fecci, Peter E., Hidenobu Ochiai, Duane A. Mitchell, Peter M. Grossi, Alison E. Sweeney, Gary E. Archer, Thomas Cummings, James P. Allison, Darell D. Bigner, and John H. Sampson. “Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.” Clin Cancer Res 13, no. 7 (April 1, 2007): 2158–67. https://doi.org/10.1158/1078-0432.CCR-06-2070.Full Text Link to Item
-
Kunwar, Sandeep, Michael D. Prados, Susan M. Chang, Mitchel S. Berger, Frederick F. Lang, Joseph M. Piepmeier, John H. Sampson, et al. “Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.” J Clin Oncol 25, no. 7 (March 1, 2007): 837–44. https://doi.org/10.1200/JCO.2006.08.1117.Full Text Link to Item
-
Sampson, John H., Raghu Raghavan, James M. Provenzale, David Croteau, David A. Reardon, R Edward Coleman, Inmaculada Rodríguez Ponce, Ira Pastan, Raj K. Puri, and Christoph Pedain. “Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.” Ajr Am J Roentgenol 188, no. 3 (March 2007): 703–9. https://doi.org/10.2214/AJR.06.0428.Full Text Link to Item
-
Soper, J. T., M. Spillman, J. H. Sampson, J. P. Kirkpatrick, J. K. Wolf, and D. L. Clarke-Pearson. “High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients.” Gynecol Oncol 104, no. 3 (March 2007): 691–94. https://doi.org/10.1016/j.ygyno.2006.10.027.Full Text Link to Item
-
Sampson, John H., Martin L. Brady, Neil A. Petry, David Croteau, Allan H. Friedman, Henry S. Friedman, Terence Wong, et al. “Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.” Neurosurgery 60, no. 2 Suppl 1 (February 2007): ONS89–98. https://doi.org/10.1227/01.NEU.0000249256.09289.5F.Full Text Link to Item
-
Learn, Chris A., Peter M. Grossi, Robert J. Schmittling, Weihua Xie, Duane A. Mitchell, Isaac Karikari, ZhengZheng Wei, Holly Dressman, and John H. Sampson. “Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.” J Neuroimmunol 182, no. 1–2 (January 2007): 63–72. https://doi.org/10.1016/j.jneuroim.2006.09.016.Full Text Link to Item
-
Learn, Chris A., Peter E. Fecci, Robert J. Schmittling, Weihua Xie, Isaac Karikari, Duane A. Mitchell, Gary E. Archer, ZhengZheng Wei, Holly Dressman, and John H. Sampson. “Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.” Clin Cancer Res 12, no. 24 (December 15, 2006): 7306–15. https://doi.org/10.1158/1078-0432.CCR-06-1727.Full Text Link to Item
-
Ochiai, Hidenobu, Chris T. Pernell, Gary E. Archer, Tracy A. Chewning, Roger E. McLendon, Henry S. Friedman, and John H. Sampson. “Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.” Neurol Med Chir (Tokyo) 46, no. 10 (October 2006): 485–89. https://doi.org/10.2176/nmc.46.485.Full Text Link to Item
-
Petrella, Jeffrey R., Lubdha M. Shah, Katy M. Harris, Allen H. Friedman, Timothy M. George, John H. Sampson, Joseph S. Pekala, and James T. Voyvodic. “Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors.” Radiology 240, no. 3 (September 2006): 793–802. https://doi.org/10.1148/radiol.2403051153.Full Text Link to Item
-
Fecci, Peter E., Alison E. Sweeney, Peter M. Grossi, Smita K. Nair, Christopher A. Learn, Duane A. Mitchell, Xiuyu Cui, et al. “Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.” Clin Cancer Res 12, no. 14 Pt 1 (July 15, 2006): 4294–4305. https://doi.org/10.1158/1078-0432.CCR-06-0053.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, et al. “Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.” J Nucl Med 47, no. 6 (June 2006): 912–18.Link to Item
-
Sampson, John H., Gamal Akabani, Allan H. Friedman, Darell Bigner, Sandeep Kunwar, Mitchel S. Berger, and Krystof S. Bankiewicz. “Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.” Neurosurg Focus 20, no. 4 (April 15, 2006): E14. https://doi.org/10.3171/foc.2006.20.4.9.Full Text Link to Item
-
Kunwar, Sandeep, Susan M. Chang, Michael D. Prados, Mitchel S. Berger, John H. Sampson, David Croteau, Jeffrey W. Sherman, et al. “Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.” Neurosurg Focus 20, no. 4 (April 15, 2006): E15.Link to Item
-
Raghavan, Raghu, Martin L. Brady, María Inmaculada Rodríguez-Ponce, Andreas Hartlep, Christoph Pedain, and John H. Sampson. “Convection-enhanced delivery of therapeutics for brain disease, and its optimization.” Neurosurg Focus 20, no. 4 (April 15, 2006): E12. https://doi.org/10.3171/foc.2006.20.4.7.Full Text Link to Item
-
Fecci, Peter E., Duane A. Mitchell, John F. Whitesides, Weihua Xie, Allan H. Friedman, Gary E. Archer, James E. Herndon, Darell D. Bigner, Glenn Dranoff, and John H. Sampson. “Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.” Cancer Res 66, no. 6 (March 15, 2006): 3294–3302. https://doi.org/10.1158/0008-5472.CAN-05-3773.Full Text Link to Item
-
Ochiai, Hidenobu, Stephanie A. Campbell, Gary E. Archer, Tracy A. Chewning, Eugenia Dragunsky, Alexander Ivanov, Matthias Gromeier, and John H. Sampson. “Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.” Clin Cancer Res 12, no. 4 (February 15, 2006): 1349–54. https://doi.org/10.1158/1078-0432.CCR-05-1595.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, Annick Desjardins, Sith Sathornsumetee, et al. “Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.” Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 860–68. https://doi.org/10.1158/1078-0432.CCR-05-2215.Full Text Link to Item
-
Reardon, David A., Merrill J. Egorin, Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James J. Vredenburgh, Annick Desjardins, et al. “Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.” J Clin Oncol 23, no. 36 (December 20, 2005): 9359–68. https://doi.org/10.1200/JCO.2005.03.2185.Full Text Link to Item
-
Sampson, J. H., T. D. Shafman, J. H. Carter, A. H. Friedman, and H. F. Seigler. “Brain metastases from malignant melanoma,” December 1, 2005, 430–38. https://doi.org/10.1016/B978-0-7216-8148-1.50059-0.Full Text
-
Quinn, Jennifer A., Annick Desjardins, Jon Weingart, Henry Brem, M Eileen Dolan, Shannon M. Delaney, James Vredenburgh, et al. “Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.” J Clin Oncol 23, no. 28 (October 1, 2005): 7178–87. https://doi.org/10.1200/JCO.2005.06.502.Full Text Link to Item
-
Little, Kenneth M., Allan H. Friedman, John H. Sampson, Masahiko Wanibuchi, and Takanori Fukushima. “Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients.” Neurosurgery 56, no. 3 (March 2005): 546–59. https://doi.org/10.1227/01.neu.0000153906.12640.62.Full Text Link to Item
-
Sampson, John H., David A. Reardon, Allan H. Friedman, Henry S. Friedman, R Edward Coleman, Roger E. McLendon, Ira Pastan, and Darell D. Bigner. “Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.” Neuro Oncol 7, no. 1 (January 2005): 90–96. https://doi.org/10.1215/S1152851703000589.Full Text Link to Item
-
Ochiai, Hidenobu, Stephanie A. Moore, Gary E. Archer, Tatsunori Okamura, Tracy A. Chewning, Jeffrey R. Marks, John H. Sampson, and Matthias Gromeier. “Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus.” Clin Cancer Res 10, no. 14 (July 15, 2004): 4831–38. https://doi.org/10.1158/1078-0432.CCR-03-0694.Full Text Link to Item
-
Merrill, Melinda K., Guenter Bernhardt, John H. Sampson, Carol J. Wikstrand, Darell D. Bigner, and Matthias Gromeier. “Poliovirus receptor CD155-targeted oncolysis of glioma.” Neuro Oncol 6, no. 3 (July 2004): 208–17. https://doi.org/10.1215/S1152851703000577.Full Text Link to Item
-
Learn, Chris A., Tristan L. Hartzell, Carol J. Wikstrand, Gary E. Archer, Jeremy N. Rich, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.” Clin Cancer Res 10, no. 9 (May 1, 2004): 3216–24. https://doi.org/10.1158/1078-0432.ccr-03-0521.Full Text Link to Item
-
Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James Vredenburgh, Sridharan Gururangan, et al. “Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.” Neuro Oncol 6, no. 2 (April 2004): 145–53. https://doi.org/10.1215/S1152851703000498.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James Vredenburgh, John H. Sampson, James M. Provenzale, et al. “Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.” Neuro Oncol 6, no. 2 (April 2004): 134–44. https://doi.org/10.1215/s1152851703000413.Full Text Link to Item
-
Sampson, John H., Peter M. Grossi, Katsuyuki Asaoka, and Takanori Fukushima. “Microvascular decompression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidance.” Neurosurgery 54, no. 4 (April 2004): 884–89. https://doi.org/10.1227/01.neu.0000114142.98655.cc.Full Text Link to Item
-
Rich, Jeremy N., David A. Reardon, Terry Peery, Jeannette M. Dowell, Jennifer A. Quinn, Kara L. Penne, Carol J. Wikstrand, et al. “Phase II trial of gefitinib in recurrent glioblastoma.” J Clin Oncol 22, no. 1 (January 1, 2004): 133–42. https://doi.org/10.1200/JCO.2004.08.110.Full Text Link to Item
-
Itharat, A., P. J. Houghton, E. Eno Amooquaye, P. J. Burke, J. H. Sampson, and A. Raman. “In vitro cytotoxic activity of Thai medicinal plants used traditionally to treat cancer.” Journal of Ethnopharmacology 90, no. 1 (January 2004): 33–38.
-
Morse, Michael A., H Kim Lyerly, Timothy M. Clay, Omar Abdel-Wahab, Stephen Y. Chui, Jennifer Garst, Jared Gollob, et al. “Immunotherapy of surgical malignancies.” Curr Probl Surg 41, no. 1 (January 2004): 15–132. https://doi.org/10.1016/S0011384003001321.Full Text Link to Item
-
Grossi, Peter M., Hidenobu Ochiai, Gary E. Archer, Roger E. McLendon, Michael R. Zalutsky, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.” Clin Cancer Res 9, no. 15 (November 15, 2003): 5514–20.Link to Item
-
Sampson, John H., Gamal Akabani, Gary E. Archer, Darell D. Bigner, Mitchel S. Berger, Allan H. Friedman, Henry S. Friedman, et al. “Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.” J Neurooncol 65, no. 1 (October 2003): 27–35. https://doi.org/10.1023/a:1026290315809.Full Text Link to Item
-
Heimberger, Amy B., Laura E. Crotty, Gary E. Archer, Kenneth R. Hess, Carol J. Wikstrand, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.” Clin Cancer Res 9, no. 11 (September 15, 2003): 4247–54.Link to Item
-
Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James M. Provenzale, Roger E. McLendon, et al. “Phase II trial of temozolomide in patients with progressive low-grade glioma.” J Clin Oncol 21, no. 4 (February 15, 2003): 646–51. https://doi.org/10.1200/JCO.2003.01.009.Full Text Link to Item
-
Fecci, Peter E., Duane A. Mitchell, Gary E. Archer, Michael A. Morse, H Kim Lyerly, Darell D. Bigner, and John H. Sampson. “The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.” J Neurooncol 64, no. 1–2 (2003): 161–76. https://doi.org/10.1007/BF02700031.Full Text Link to Item
-
Mitchell, Duane A., Peter E. Fecci, and John H. Sampson. “Adoptive immunotherapy for malignant glioma.” Cancer J 9, no. 3 (2003): 157–66. https://doi.org/10.1097/00130404-200305000-00004.Full Text Link to Item
-
Heimberger, Amy B., Chris A. Learn, Gary E. Archer, Roger E. McLendon, Tracy A. Chewning, Frank L. Tuck, John B. Pracyk, et al. “Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).” Clin Cancer Res 8, no. 11 (November 2002): 3496–3502.Link to Item
-
Fecci, Peter E., Matthias Gromeier, and John H. Sampson. “Viruses in the treatment of brain tumors.” Neuroimaging Clin N Am 12, no. 4 (November 2002): 553–70. https://doi.org/10.1016/s1052-5149(02)00028-x.Full Text Link to Item
-
Fecci, Peter E., and John H. Sampson. “Clinical immunotherapy for brain tumors.” Neuroimaging Clin N Am 12, no. 4 (November 2002): 641–64. https://doi.org/10.1016/s1052-5149(02)00027-8.Full Text Link to Item
-
Asaoka, Katsuyuki, David M. Barrs, John H. Sampson, John T. McElveen, Debara L. Tucci, and Takanori Fukushima. “Intracanalicular meningioma mimicking vestibular schwannoma.” Ajnr Am J Neuroradiol 23, no. 9 (October 2002): 1493–96.Link to Item
-
Lal, Anita, Chad A. Glazer, Holly M. Martinson, Henry S. Friedman, Gary E. Archer, John H. Sampson, and Gregory J. Riggins. “Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.” Cancer Res 62, no. 12 (June 15, 2002): 3335–39.Link to Item
-
Quinn, Jennifer A., James Pluda, M Eileen Dolan, Shannon Delaney, Richard Kaplan, Jeremy N. Rich, Allan H. Friedman, et al. “Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.” J Clin Oncol 20, no. 9 (May 1, 2002): 2277–83. https://doi.org/10.1200/JCO.2002.09.084.Full Text Link to Item
-
Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Ilkcan Cokgor, et al. “Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.” J Clin Oncol 20, no. 5 (March 1, 2002): 1389–97. https://doi.org/10.1200/JCO.2002.20.5.1389.Full Text Link to Item
-
Wikstrand, Carol J., Vanessa R. Cole, Laura E. Crotty, John H. Sampson, and Darell D. Bigner. “Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.” Cancer Immunol Immunother 50, no. 12 (February 2002): 639–52. https://doi.org/10.1007/s00262-001-0243-5.Full Text Link to Item
-
Heimberger, Amy B., Gary E. Archer, Laura E. Crotty, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.” Neurosurgery 50, no. 1 (January 2002): 158–64. https://doi.org/10.1097/00006123-200201000-00024.Full Text Link to Item
-
Gururangan, S., L. Cokgor, J. N. Rich, S. Edwards, M. L. Affronti, J. A. Quinn, J. E. Herndon, et al. “Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.” Neuro Oncol 3, no. 4 (October 2001): 246–50. https://doi.org/10.1093/neuonc/3.4.246.Full Text Link to Item
-
Sampson, J. H., A. Raman, G. Karlsen, H. Navsaria, and I. M. Leigh. “In vitro keratinocyte antiproliferant effect of Centella asiatica extract and triterpenoid saponins.” Phytomedicine 8, no. 3 (May 2001): 230–35. https://doi.org/10.1078/0944-7113-00032.Full Text Link to Item
-
Friedman, H. S., J. Pluda, J. A. Quinn, R. B. Ewesuedo, L. Long, A. H. Friedman, I. Cokgor, et al. “Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.” J Clin Oncol 18, no. 20 (October 15, 2000): 3522–28. https://doi.org/10.1200/JCO.2000.18.20.3522.Full Text Link to Item
-
Heimberger, A. B., G. E. Archer, R. E. McLendon, C. Hulette, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.” Clin Cancer Res 6, no. 10 (October 2000): 4148–53.Link to Item
-
Wikstrand, C. J., J. H. Sampson, and D. D. Bigner. “EGFRvIII: An oncogene deletion mutant cell surface receptor target expressed by multiple tumour types.” Expert Opinion on Therapeutic Targets 4, no. 4 (August 1, 2000): 497–514. https://doi.org/10.1517/14728222.4.4.497.Full Text
-
Sampson, J. H., L. E. Crotty, S. Lee, G. E. Archer, D. M. Ashley, C. J. Wikstrand, L. P. Hale, et al. “Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.” Proc Natl Acad Sci U S A 97, no. 13 (June 20, 2000): 7503–8. https://doi.org/10.1073/pnas.130166597.Full Text Link to Item
-
Heimberger, A. B., L. E. Crotty, G. E. Archer, R. E. McLendon, A. Friedman, G. Dranoff, D. D. Bigner, and J. H. Sampson. “Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma.” J Neuroimmunol 103, no. 1 (February 1, 2000): 16–25. https://doi.org/10.1016/s0165-5728(99)00172-1.Full Text Link to Item
-
Sampson, J. H., J. D. Phillipson, N. G. Bowery, M. J. O’Neill, J. G. Houston, and J. A. Lewis. “Ethnomedicinally selected plants as sources of potential analgesic compounds: indication of in vitro biological activity in receptor binding assays.” Phytother Res 14, no. 1 (February 2000): 24–29. https://doi.org/10.1002/(sici)1099-1573(200002)14:1<24::aid-ptr537>3.0.co;2-9.Full Text Link to Item
-
Archer, G. E., J. H. Sampson, I. A. Lorimer, R. E. McLendon, C. T. Kuan, A. H. Friedman, H. S. Friedman, I. H. Pastan, and D. D. Bigner. “Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.” Clin Cancer Res 5, no. 9 (September 1999): 2646–52.Link to Item
-
Sampson, J. H., G. E. Archer, A. T. Villavicencio, R. E. McLendon, A. H. Friedman, W. R. Bishop, D. D. Bigner, and H. S. Friedman. “Treatment of neoplastic meningitis with intrathecal temozolomide.” Clin Cancer Res 5, no. 5 (May 1999): 1183–88.Link to Item
-
Sampson, J. H. “The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif.” Neuro Oncol 1, no. 1 (January 1999): 33–42. https://doi.org/10.1093/neuonc/1.1.33.Full Text Link to Item
-
Archer, G. E., J. H. Sampson, R. E. McLendon, A. H. Friedman, O. M. Colvin, M. Rose, H. Sands, et al. “Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.” J Neurooncol 44, no. 3 (1999): 233–41. https://doi.org/10.1023/a:1006304424346.Full Text Link to Item
-
Wikstrand, C. J., I. Cokgor, J. H. Sampson, and D. D. Bigner. “Monoclonal antibody therapy of human gliomas: current status and future approaches.” Cancer Metastasis Rev 18, no. 4 (1999): 451–64. https://doi.org/10.1023/a:1006354102377.Full Text Link to Item
-
Green, L. A., F. S. Rhame, R. W. Price, D. C. Perlman, L. G. Capps, J. H. Sampson, L. R. Deyton, et al. “Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS.” Aids 12, no. 15 (October 22, 1998): 1983–90. https://doi.org/10.1097/00002030-199815000-00009.Full Text Link to Item
-
Ashley, D. M., J. H. Sampson, G. E. Archer, L. P. Hale, and D. D. Bigner. “Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model.” J Neuroimmunol 86, no. 1 (June 1, 1998): 46–52. https://doi.org/10.1016/s0165-5728(98)00017-4.Full Text Link to Item
-
Brosgart, C. L., T. A. Louis, D. W. Hillman, C. P. Craig, B. Alston, E. Fisher, D. I. Abrams, et al. “A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS.” Aids 12, no. 3 (February 12, 1998): 269–77. https://doi.org/10.1097/00002030-199803000-00004.Full Text Link to Item
-
Sampson, J. H., J. H. Carter, A. H. Friedman, and H. F. Seigler. “Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.” J Neurosurg 88, no. 1 (January 1998): 11–20. https://doi.org/10.3171/jns.1998.88.1.0011.Full Text Link to Item
-
Sampson, J. H., D. M. Ashley, G. E. Archer, H. E. Fuchs, G. Dranoff, L. P. Hale, and D. D. Bigner. “Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.” Neurosurgery 41, no. 6 (December 1997): 1365–72. https://doi.org/10.1097/00006123-199712000-00024.Full Text Link to Item
-
Ashley, D. M., J. H. Sampson, G. E. Archer, S. K. Batra, D. D. Bigner, and L. P. Hale. “A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.” J Neuroimmunol 78, no. 1–2 (September 1997): 34–46. https://doi.org/10.1016/s0165-5728(97)00080-5.Full Text Link to Item
-
Archer, G. E., J. H. Sampson, and D. D. Bigner. “Viruses and oncogenes in brain tumors.” J Neurovirol 3 Suppl 1 (May 1997): S76–77.Link to Item
-
Timpone, J. G., D. J. Wright, N. Li, M. J. Egorin, M. E. Enama, J. Mayers, and G. Galetto. “The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative.” Aids Res Hum Retroviruses 13, no. 4 (March 1, 1997): 305–15. https://doi.org/10.1089/aid.1997.13.305.Full Text Link to Item
-
Gordin, F. M., E. T. Nelson, J. P. Matts, D. L. Cohn, J. Ernst, D. Benator, C. L. Besch, et al. “The impact of human immunodeficiency virus infection on drug-resistant tuberculosis.” Am J Respir Crit Care Med 154, no. 5 (November 1996): 1478–83. https://doi.org/10.1164/ajrccm.154.5.8912768.Full Text Link to Item
-
Sampson, J. H., G. E. Archer, D. M. Ashley, H. E. Fuchs, L. P. Hale, G. Dranoff, and D. D. Bigner. “Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.” Proc Natl Acad Sci U S A 93, no. 19 (September 17, 1996): 10399–404. https://doi.org/10.1073/pnas.93.19.10399.Full Text Link to Item
-
Gabriel, E. M., J. H. Sampson, and R. H. Wilkins. “Recurrence of a cerebral arteriovenous malformation after surgical excision. Case report.” J Neurosurg 84, no. 5 (May 1996): 879–82. https://doi.org/10.3171/jns.1996.84.5.0879.Full Text Link to Item
-
Gabriel, E. M., J. H. Sampson, L. G. Dodd, and D. A. Turner. “Glomus jugulare tumor metastatic to the sacrum after high-dose radiation therapy: case report.” Neurosurgery 37, no. 5 (November 1995): 1001–5. https://doi.org/10.1227/00006123-199511000-00022.Full Text
-
Spiegel, D. A., J. H. Sampson, W. J. Richardson, A. H. Friedman, E. Rossitch, W. T. Hardaker, and H. F. Seigler. “Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients.” Spine (Phila Pa 1976) 20, no. 19 (October 1, 1995): 2141–46. https://doi.org/10.1097/00007632-199510000-00013.Full Text Link to Item
-
Sampson, J. H., R. E. Cashman, B. S. Nashold, and A. H. Friedman. “Dorsal root entry zone lesions for intractable pain after trauma to the conus medullaris and cauda equina.” J Neurosurg 82, no. 1 (January 1995): 28–34. https://doi.org/10.3171/jns.1995.82.1.0028.Full Text Link to Item
-
Sampson, J. H., and J. Neaton. “On being poor with HIV.” Lancet 344, no. 8930 (October 22, 1994): 1100–1101. https://doi.org/10.1016/s0140-6736(94)90623-8.Full Text Link to Item
-
Dohn, M. N., W. G. Weinberg, R. A. Torres, S. E. Follansbee, P. T. Caldwell, J. D. Scott, J. C. Gathe, et al. “Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group.” Ann Intern Med 121, no. 3 (August 1, 1994): 174–80. https://doi.org/10.7326/0003-4819-121-3-199408010-00003.Full Text Link to Item
-
Sampson, J. H., and E. R. Cardoso. “The gravitational shunt: an alternative approach to cerebrospinal fluid shunting.” Surg Neurol 40, no. 2 (August 1993): 112–18. https://doi.org/10.1016/0090-3019(93)90120-p.Full Text Link to Item
-
Sampson, J. H., A. H. Friedman, H. F. Seigler, and J. H. Carter. “Epidural spinal metastases from malignant melanoma: Demographics, prognosis and treatment.” Canadian Journal of Neurological Sciences 20:S25 (1993).
-
Sampson, J. H., E. Rossitch, J. N. Young, K. L. Lane, and A. H. Friedman. “Solitary eosinophilic granuloma invading the clivus of an adult: case report.” Neurosurgery 31, no. 4 (October 1992): 755–57. https://doi.org/10.1227/00006123-199210000-00022.Full Text
-
Sampson, J. H., and B. S. Nashold. “Facial pain due to vascular lesions of the brain stem relieved by dorsal root entry zone lesions in the nucleus caudalis. Report of two cases.” J Neurosurg 77, no. 3 (September 1992): 473–75. https://doi.org/10.3171/jns.1992.77.3.0473.Full Text Link to Item
-
Sampson, J. H., E. Rossitch, and W. J. Oakes. “Initial management of pediatric head trauma.” Am Fam Physician 45, no. 6 (June 1992): 2621–28.Link to Item
-
Reuler, J. B., M. J. Bax, and J. H. Sampson. “Physician house call services for medically needy, inner-city residents.” American Journal of Public Health 76, no. 9 (September 1986): 1131–34.
-
Levinson, W., P. M. Dunn, T. G. Cooney, and J. H. Sampson. “Parasitic infections in asymptomatic homosexual men: cost-effective screening.” Journal of General Internal Medicine : Official Journal of the Society for Research and Education in Primary Care Internal Medicine 1, no. 3 (1986): 150–54.
-
Sampson, J. H., N. J. Alexander, D. L. Fulgham, and K. A. Burry. “Gender after artificial induction of ovulation and artificial insemination.” Fertility and Sterility 40, no. 4 (October 1983): 481–84.
-
Alexander, N. J., J. H. Sampson, and D. L. Fulgham. “Pregnancy rates in patients treated for antisperm antibodies with prednisone.” International Journal of Fertility 28, no. 2 (1983): 63–67.
-
Hall Patch, P. K., R. G. Orton, and J. H. Sampson. “Competitive trail and endurance riding in the UK.” The Veterinary Record 100, no. 10 (March 1977): 192–94.
-
Burlington, R. F., and J. H. Sampson. “Distribution and activity of lactic dehydrogenase isozymes in tissues from a hibernator and a non-hibernator.” Comparative Biochemistry and Physiology 25, no. 1 (April 1968): 185–92.
-
Sampson, J. H. “A Note on Automorphic Varieties.” Proceedings of the National Academy of Sciences of the United States of America 38, no. 10 (October 1952): 895–98.
-
-
Book Sections
-
Batich, K. A., A. N. Bramall, C. M. Suryadevara, and J. H. Sampson. “Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors.” In Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition, 693–705, 2018. https://doi.org/10.1016/B978-0-12-812100-9.00055-3.Full Text
-
Bramall, A. N., A. Friedman, and J. H. Sampson. “Complications after glioma surgery.” In Complications in Neurosurgery, 107–13, 2018. https://doi.org/10.1016/B978-0-323-50961-9.00021-9.Full Text
-
Chandramohan, V., J. H. Sampson, I. H. Pastan, and D. D. Bigner. “Immunotoxin Therapy for Brain Tumors.” In Translational Immunotherapy of Brain Tumors, 227–60, 2017. https://doi.org/10.1016/B978-0-12-802420-1.00010-7.Full Text
-
Riccione, K. A., P. Gedeon, L. Sanchez-Perez, and J. H. Sampson. “Checkpoint Blockade Immunotherapy for Glioblastoma: Progress and Challenges.” In Translational Immunotherapy of Brain Tumors, 261–300, 2017. https://doi.org/10.1016/B978-0-12-802420-1.00011-9.Full Text
-
Komisarow, J. M., and J. H. Sampson. “An Introduction to Immunotherapy in the Treatment of Brain Tumors.” In Translational Immunotherapy of Brain Tumors, 1–10, 2017. https://doi.org/10.1016/B978-0-12-802420-1.00001-6.Full Text
-
Fecci, P. E., K. Riccione, G. P. Dunn, E. Reap, G. Vlahovic, K. Congdon, and J. H. Sampson. “Immunotherapy for gliomas.” In The Duke Glioma Handbook: Pathology, Diagnosis, and Management, 91–120, 2016. https://doi.org/10.1017/CBO9781107588721.006.Full Text
-
Kirkpatrick, J. P., G. Kim, and J. H. Sampson. “Radiation therapy for gliomas.” In The Duke Glioma Handbook: Pathology, Diagnosis, and Management, 49–75, 2016. https://doi.org/10.1017/CBO9781107588721.004.Full Text
-
hansen, L. H., B. Diplas, B. becher, and B. Yan. “Genetics of glioma.” In The Duke Glioma Handbook, translated by J. H. S. Sampson. Cambridge University Press, 2016.Link to Item
-
Schaller, T. H., and J. H. Sampson. “Immunotherapy for high-grade gliomas.” In Malignant Brain Tumors: State-of-the-Art Treatment, 177–92, 2016. https://doi.org/10.1007/978-3-319-49864-5_12.Full Text
-
Batich, Kristen A., Adam M. Swartz, and John H. Sampson. “Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy.,” 1403:819–38, 2016. https://doi.org/10.1007/978-1-4939-3387-7_47.Full Text Link to Item
-
Choi, Bryan D., Peter E. Fecci, and John H. Sampson. “Immunobiology and Immune Therapy.” In NEURO-ONCOLOGY: THE ESSENTIALS, 3RD EDITION, 254–63, 2015.Link to Item
-
Choi, Bryan D., Kevin S. Chen, and John H. Sampson. “Malignant Glioma Immunotherapy: A Peptide Vaccine from Bench to Bedside.” In Tumors of the Central Nervous System, Volume 1, 349–56. Springer Netherlands, 2011. https://doi.org/10.1007/978-94-007-0344-5_36.Full Text
-
New, K. C., D. C. Adamson, L. Selznick, and J. Sampson. “Novel therapeutic approaches for high-grade gliomas.” In Modern Neurosurgery: Clinical Translation of Neuroscience Advances, 159–84, 2004.
-
-
Conference Papers
-
Desjardins, Annick, Vidyalakshmi Chandramohan, Daniel B. Landi, Margaret O. Johnson, Mustafa Khasraw, Katherine B. Peters, Justin Low, et al. “A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).” In Journal of Clinical Oncology, Vol. 40, 2022.Link to Item
-
Sampson, John H., Kristen A. Batich, Duane Anthony Mitchell, James Emmett Herndon, Gloria Broadwater, Patrick Healy, Luis Sanchez-Perez, et al. “Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma.” In Journal of Clinical Oncology, Vol. 40, 2022.Link to Item
-
Singh, Kirit, Matthew Foster, Elizabeth S. Miller, Simon Gregory, Kent J. Weinhold, David M. Ashley, Annick Desjardins, et al. “A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.” In Journal of Clinical Oncology, Vol. 40, 2022.Link to Item
-
Batich, Kristen, Duane Mitchell, Patrick Healy, James Herndon, Gloria Broadwater, Gunn Michael, Min-Nung Huang, et al. “CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA.” In Neuro Oncology, 23:vi51–vi51. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.202.Full Text Open Access Copy Link to Item
-
Chakraborty, Molly Antara, William H. Tomaszewski, Jessica Waibl Polania, Luigi Racioppi, Luis A. Sanchez-Perez, Michael D. Gunn, and John H. Sampson. “CaMKK2 deletion causes increased accumulation of CD4+TILs and an improved ratio of effector memory TILs to Tregs.” In Journal of Immunology, Vol. 206, 2021.Link to Item
-
Perera, Jonathan J., William H. Tomaszewski, Jessica Waibl Polania, Luigi Racioppi, Luis A. Sanchez-Perez, Michael D. Gunn, and John H. Sampson. “CaMKK2 deletion increases antitumor potential through enhanced MHC-II expression in Macrophages.” In Journal of Immunology, Vol. 206, 2021.Link to Item
-
Thompson, Eric, Daniel Landi, Eric Lipp, Bea Balajonda, James Herndon, Evan Buckley, Charlene Flahiff, et al. “CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL.” In Neuro Oncology, 22:ii37–ii37. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa215.155.Full Text Open Access Copy Link to Item
-
Desjardins, Annick, Dina Randazzo, Vidyalakshmi Chandramohan, Peters Katherine B., Margaret O. Johnson, Steve Threat, Chevelle A. Bullock, et al. “Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).” In Journal of Clinical Oncology, 38:20s-20s. American Society of Clinical Oncology, 2020. https://doi.org/10.1200/JCO.2020.38.15_suppl.2566.Full Text Link to Item
-
Schaller, Teilo H., Kristen A. Batich, Kelly Hotchkiss, Xiuyu Cui, Luis Sanchez-Perez, and John H. Sampson. “The effects of CCL3 on dendritic cell migration and immune cell activation.” In Cancer Immunology Research, 8:74–75. AMER ASSOC CANCER RESEARCH, 2020.Link to Item
-
Desjardins, Annick, Dina Randazzo, Vidyalakshmi Chandramohan, Katherine B. Peters, Margaret O. Johnson, Stevie Threatt, Chevelle A. Bullock, et al. “Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).” In Journal of Clinical Oncology, Vol. 38, 2020.Link to Item
-
Sampson, John H., Achal Achrol, Manish K. Aghi, Krystof Bankiewicz, Martin Bexon, Steven Brem, Andrew Jacob Brenner, et al. “MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.” In Journal of Clinical Oncology, Vol. 38, 2020.Link to Item
-
Swartz, Adam, Katherine Riccione, Kendra Congdon, Luis A. Sanchez-Perez, Smita K. Nair, and John H. Sampson. “Synthetic long peptide vaccines possessing a universal helper epitope can unmask the therapeutic effects of MHC I-restricted neoepitopes.” In Journal of Immunology, Vol. 204, 2020.Link to Item
-
Desjardins, Annick, Matthias Gromeier, James Emmett Herndon, Dina Randazzo, Stevie Threatt, Eric S. Lipp, Elizabeth S. Miller, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.” In Journal of Clinical Oncology, 37:101s-101s. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.2060.Full Text Link to Item
-
Peters, Katherine B., Gerald E. Archer, Pamela Norberg, Weihua Xie, Stevie Threatt, Eric S. Lipp, James Emmett Herndon, et al. “Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.” In Journal of Clinical Oncology, 37:e13526–e13526. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e13526.Full Text
-
Randazzo, Dina, Achal Achrol, Manish K. Aghi, Martin Bexon, Steven Brem, Andrew Jacob Brenner, Nicholas A. Butowski, et al. “MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.” In Journal of Clinical Oncology, 37:2039–2039. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.2039.Full Text Link to Item
-
Huang, Min-Nung, Lowell T. Nicholson, Kristen A. Batich, David Kopin, Adam M. Swartz, John H. Sampson, and Michael Dee Gunn. “Monocytes outperform ex vivo generated dendritic cells as cellular vaccines to trigger cytotoxic T lymphocyte responses against cancer in pre-clinical models.” In Journal of Immunology, Vol. 202. AMER ASSOC IMMUNOLOGISTS, 2019.Link to Item
-
Gedeon, Patrick C., Carter M. Suryadevara, Bryan D. Choi, and John H. Sampson. “The effect of adoptive transfer of ex vivo activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.” In Journal of Clinical Oncology, 37:30–30. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.8_suppl.30.Full Text
-
Bexon, M. F., A. Achrol, K. Bankiewicz, A. Brenner, N. Butowski, S. Kesari, F. Merchant, et al. “Understanding biological activity, tumor response and pseudoprogression in a phase-IIb study of MDNA55 in adults with recurrent or progressive glioblastoma (GB).” In Annals of Oncology, 29:viii124–25. Oxford University Press (OUP), 2018. https://doi.org/10.1093/annonc/mdy273.Full Text Link to Item
-
Ashley, David M., Eric M. Thompson, Daniel Landi, Annick Desjardins, Allan H. Friedman, Stevie Threatt, James E. Herndon, et al. “PHASE 1B STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN.” In Neuro Oncology, 20:93–93. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Congdon, Kendra L., Luis A. Sanchez-Perez, and John H. Sampson. “Abstract CN02-02: Immunotherapy for central nervous system cancers.” In Molecular Cancer Therapeutics, Vol. 17. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/1535-7163.targ-17-cn02-02.Full Text
-
Elsamadicy, Aladine A., Amanda Sergesketter, John H. Sampson, and Oren N. Gottfried. “165 Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients.” In Neurosurgery, 64:241–42. Ovid Technologies (Wolters Kluwer Health), 2017. https://doi.org/10.1093/neuros/nyx417.165.Full Text
-
Desjardins, Annick, John H. Sampson, Gordana Vlahovic, Katherine B. Peters, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).” In Journal of Clinical Oncology, 35:e13533–e13533. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e13533.Full Text Link to Item
-
Randazzo, Dina, Annick Desjardins, Vidyalakshmi Chandramohan, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Stevie Threatt, et al. “Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.” In Journal of Clinical Oncology, 35:e13532–e13532. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.e13532.Full Text Link to Item
-
Dunn-Pirio, Anastasie, Katherine Peters, Dina Randazzo, Hentry Friedman, Patrick Healy, James Herndon, Elizabeth Reap, et al. “Tumor stem cell RNA-leaded dedritic cell vaccine for recurrent glioblastoma: a phase 1 trail.” In Neurology, 88:S41–S41. American Academy of Neurology, 2017.Link to Item
-
Gedeon, Patrick C., Teilo H. Schaller, Carter M. Suryadevara, Bryan D. Choi, Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Darell D. Bigner, and John H. Sampson. “A FULLY-HUMAN EGFRvIII-TARGETED BISPECIFIC ANTIBODY REDIRECTS HUMAN T CELLS TO SPECIFICALLY LYSE MALIGNANT GLIOMA.” In Neuro Oncology, 18:96–96. OXFORD UNIV PRESS INC, 2016.Link to Item
-
Riccione, Katherine, Luis Riccione, and John H. Sampson. “DEVELOPMENT OF A PEPTIDE VACCINE PLATFORM FOR BRAIN TUMOR IMMUNOTHERAPY THAT INCORPORATES ADJUVANT CD27 STIMULATION FOR ENHANCED T CELL IMMUNITY.” In Neuro Oncology, 18:98–98. OXFORD UNIV PRESS INC, 2016.Link to Item
-
Suryadevara, Carter M., Pakawat Chongsathidkiet, Katherine Riccione, Patrick C. Gedeon, Rupen Desai, Bryan D. Choi, David J. Snyder, et al. “CAR T CELLS INDUCE COMPLETE REGRESSION OF MURINE GLIOBLASTOMA AFTER PRECONDITIONING HOSTS WITH TEMOZOLOMIDE.” In Neuro Oncology, 18:94–95. OXFORD UNIV PRESS INC, 2016.Link to Item
-
Suryadevara, Carter M., Rupen Desai, David J. Snyder, Qi-Jing Li, Peter E. Fecci, Luis Sanchez-Perez, and John H. Sampson. “LYMPHOPENIA ENHANCES THE EFFICACY OF CAR T CELLS DELIVERED LOCO-REGIONALLY IN THE BRAIN FOR THE TREATMENT OF GLIOBLASTOMA.” In Neuro Oncology, 18:96–96. OXFORD UNIV PRESS INC, 2016.Link to Item
-
Sampson, John H. “Advances in Immunotherapy: Abhijit Guha Award Presentation.” In Neurosurgery, 63 Suppl 1:85–87, 2016. https://doi.org/10.1227/NEU.0000000000001286.Full Text Link to Item
-
Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.” In Journal of Clinical Oncology, 34:2061–2061. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2061.Full Text Link to Item
-
Sampson, John H., Antonio Marcilio Padula Omuro, Matthias Preusser, Michael Lim, Nicholas A. Butowski, Timothy Francis Cloughesy, Lewis C. Strauss, et al. “A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.” In Journal of Clinical Oncology, 34:TPS2079–TPS2079. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps2079.Full Text
-
Vlahovic, Gordana, Gerald E. Archer, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, Patrick Healy, et al. “Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 34:e13518–e13518. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e13518.Full Text Link to Item
-
Batich, Kristen, John H. Sampson, Elizabeth Reap, Luis Sanchez-Perez, Gary Archer, David Snyder, Smita Nair, Michael Gunn, and Duane Mitchell. “Tetanus toxoid conditioning enhances migration and efficacy of dendritic cell vaccines in patients with glioblastoma.” In Journal of Neurosurgery, 122:A1522–A1522. AMER ASSOC NEUROLOGICAL SURGEONS, 2015.Link to Item
-
Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.” In Journal of Clinical Oncology, 33:2068–2068. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2068.Full Text
-
Reardon, David A., James Schuster, David Dinh Tran, Karen L. Fink, Louis B. Nabors, Gordon Li, Daniela Annenelie Bota, et al. “ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.” In Journal of Clinical Oncology, 33:2009–2009. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2009.Full Text
-
Sampson, John H., Gordana Vlahovic, Solmaz Sahebjam, Antonio Marcilio Padula Omuro, Joachim M. Baehring, David A. Hafler, Alfredo Daniel Voloschin, et al. “Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.” In Journal of Clinical Oncology, 33:3010–3010. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3010.Full Text
-
Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, et al. “Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 33:e13030–e13030. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13030.Full Text
-
Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Jason Watts, Stevie Threatt, et al. “Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2106–TPS2106. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2106.Full Text
-
Friedman, Henry S., James Emmett Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, et al. “Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.” In Journal of Clinical Oncology, 32:2082–2082. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.2082.Full Text
-
Sampson, John Howard, Gordana Vlahovic, Annick Desjardins, Henry S. Friedman, Joachim M. Baehring, David Hafler, Linda Rollin, Vlad Coric, Susan N. Perez, and David A. Reardon. “Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2101–TPS2101. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2101.Full Text
-
Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Sharon Norman, Annick Desjardins, Katherine B. Peters, Tulika Ranjan, et al. “Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 32:3069–3069. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.3069.Full Text
-
Desjardins, Annick, J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Intratumoral administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in recurrent glioblastoma(GBM): Preliminary results of the Phase I clinical trial.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-CT416.Full Text Link to Item
-
Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Ranjan, Tulika, Katherine B. Peters, Gordana Vlahovic, Lloyd M. Alderson, James Emmett Herndon, Frances McSherry, Stevie Threatt, et al. “Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Gromeier, Matthias, Annick Desjardins, John H. Sampson, Stevie J. E. Threatt, James E. Herndon, Allan Friedman, Henry S. Friedman, and Darell D. Bigner. “ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF PRIMARY CNS TUMORS.” In Neuro Oncology, 15:20–20. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Pham, Christina D., Yanxin Pei, Catherine Flores, David Snyder, Darell D. Bigner, John H. Sampson, Robert J. Wechsler-Reya, and Duane A. Mitchell. “DEVELOPMENTALLY REGULATED ANTIGENS FOR IMMUNOLOGIC TARGETING OF MEDULLOBLASTOMA SUBTYPES.” In Neuro Oncology, 15:42–43. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31, 2013.Link to Item
-
Archer, Gary E., Weihua Xie, Pamela Norberg, Anjelika Dechkovskaia, Allan Friedman, Darell D. Bigner, Duane A. Mitchell, John H. Sampson, and David Boczkowski. “FEASIBILITY OF AMPLIFIED CD133((+)) BRAIN TUMOR STEM CELL RNA-PULSED DENDRITIC CELLS FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 14:49–49. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Brown, Kristine E., Stephen T. Keir, John H. Sampson, Darell D. Bigner, and Madan M. Kwatra. “NEUROKININ-1 RECEPTOR: A POTENTIAL TARGET TO INHIBIT PEDIATRIC GLIOBLASTOMAS.” In Neuro Oncology, 14:17–18. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Choi, Bryan D., Chien-Tsun Kuan, Mingqing Cai, Darell D. Bigner, and John H. Sampson. “INTRAVENOUS TREATMENT WITH AN ENDOTHELIAL GROWTH FACTOR RECEPTOR VIII-TARGETED BISPECIFIC ANTIBODY SUCCESSFULLY TREATS WELL-ESTABLISHED BRAIN TUMORS.” In Neuro Oncology, 14:38–39. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Desjardins, Annick, Katherine B. Peters, James E. Herndon, Leigh Ann Bailey, Lloyd M. Alderson, Tulika Ranjan, John H. Sampson, et al. “NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH GLIADEL (R) FOLLOWED BY RADIATION THERAPY (RT), TEMOZOLOMIDE AND BEVACIZUMAB, AND POST-RT BEVACIZUMAB AND TEMOZOLOMIDE: A PHASE II STUDY.” In Neuro Oncology, 14:104–104. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Flores, Catherine T., David Snyder, Luis Sanchez-Perez, Christina Pham, Henry Friedman, Darell D. Bigner, John H. Sampson, and Duane A. Mitchell. “ROLE OF HEMATOPOIETIC STEM CELLS IN ENHANCING THE ANTI-TUMOR EFFICACY OF ADOPTIVE CELLULAR THERAPY.” In Neuro Oncology, 14:35–35. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Nair, Smita, Robert Schmittling, David Boczkowski, Gerald Archer, Darell D. Bigner, John H. Sampson, and Duane A. Mitchell. “TARGETING CYTOMEGALOVIRUS ANTIGENS FOR GLIOBLASTOMA IMMUNOTHERAPY.” In Neuro Oncology, 14:32–32. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Pham, Christina D., Catherine Flores, David Snyder, Darrel D. Bigner, John H. Sampson, and Duane A. Mitchell. “DEVELOPMENT OF IMMUNOCOMPETENT SYNGENEIC MODELS OF MEDULLOBLASTOMA FOR EVALUATION OF IMMUNOTHERAPY.” In Neuro Oncology, 14:163–163. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Sanchez-Perez, Luis, Bryan Choi, David Snyder, Xiuyu Cui, Robert J. Schmittling, Catherine Flores, Laura Johnson, et al. “MYELOABLATIVE TEMOZOLOMIDE INCREASES ANTIGEN-SPECIFIC CD8(+) T-CELL VACCINE RESPONSES AND IS REQUIRED FOR EFFICACIOUS IMMUNOTHERAPY AGAINST INTRACEREBRAL TUMORS.” In Neuro Oncology, 14:40–40. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Sayour, Elias J., Luis Sanchez-Perez, Christina Pham, David Snyder, Weihua Xie, Xiuyu Cui, Darell D. Bigner, John H. Sampson, and Duane A. Mitchell. “DEVELOPING RNA NANOPARTICLE VACCINES TARGETING PEDIATRIC AND ADULT BRAIN TUMORS.” In Neuro Oncology, 14:39–39. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Sayour, Elias J., Pat McLendon, Renee Reynolds, Darell D. Bigner, John H. Sampson, Roger McLendon, and Duane A. Mitchell. “ASSESSMENT OF INTRATUMORAL TREGS AND CLINICAL OUTCOMES IN PRIMARY AND RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 14:39–39. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Yang, Shicheng, Gary E. Archer, Hongsheng Miao, Xiuyu Cui, Weihua Xie, David Snyder, Andrea J. Pretorian, et al. “EX VIVO GENERATION OF CENTRAL MEMORY-LIKE ANTI-TUMOR T CELLS TO TREAT MALIGNANT BRAIN TUMORS.” In Neuro Oncology, 14:45–45. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Desjardins, Annick, James J. Vredenburgh, Katherine B. Peters, Stevie Threatt, James Emmett Herndon, John Howard Sampson, Allan H. Friedman, Henry S. Friedman, and David A. Reardon. “Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Friedman, Henry S., Annick Desjardins, Katherine B. Peters, David A. Reardon, John Kirkpatrick, James Emmett Herndon, April D. Coan, et al. “The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Ronald G. Steis, Erin M. Dunbar, Nitin B. Chandramouli, Olivier Rixe, Jennifer A. Green, Thomas A. Davis, and John Howard Sampson. “REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Vredenburgh, James J., Annick Desjardins, Katherine B. Peters, David A. Reardon, James Emmett Herndon, April D. Coan, John Kirkpatrick, et al. “Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Johnson, Laura A., Gary E. Archer, Smita K. Nair, Robert Schmittling, Elizabeth Reap, and John H. Sampson. “CYTOMEGALOVIRUS-SPECIFIC IMMUNE DEFICITS IN PATIENTS WITH GBM.” In Neuro Oncology, 13:39–39. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Cuneo, Kyle C., James J. Vredenburgh, John H. Sampson, David A. Reardon, Annick Desjardins, Katherine L. Peters, and John P. Kirkpatrick. “USE OF BIOCHEMOTHERAPY AND STEREOTACTIC RADIOSURGERY IN THE MANAGEMENT OF RECURRENT MALIGNANT GLIOMA.” In Neuro Oncology, 12:107–107. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Mitchell, Duane A., Gary E. Archer, Darell D. Bigner, Henry S. Friedman, Denise Lally-Goss, Beth Perry, James E. Herndon, et al. “RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma.” In Molecular Therapy, 17:S93–S93. NATURE PUBLISHING GROUP, 2009.Link to Item
-
Desjardins, Annick, David A. Reardon, Katherine B. Peters, James Herndon, John Kirkpatrick, Sridharan Gururangan, John H. Sampson, Allan H. Friedman, Henry Friedman, and James J. Vredenburgh. “BEVACIZUMAB (BV) IN COMBINATION TO TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): A PHASE 2 TRIAL.” In Neuro Oncology, 11:634–634, 2009.Link to Item
-
Desjardins, Annick, Dina Randazzo, V. Chandramohan, Katherine B. Peters, Margaret O. Johnson, Steve Threatt, James E. Herndon, et al. “Dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for recurrent malignant glioma.,” n.d.
-
Desjardins, Annick, Dina Randazzo, V. Chandramohan, Katherine Peters, Margaret O. Johnson, Stevie Threatt, James Herndon, et al. “Dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for recurrent malignant glioma.,” n.d.
-
Desjardins, Annick, John Sampson, Katherine Peters, Gordana Vlahoci, Dina Randazzo, Stevie Threatt, James Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.,” 33:112s-112s, n.d.Link to Item
-
Weant, Mallika, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” In Neuro Oncology, Vol. 17. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov206.13.Full Text Link to Item
-
Weant, Mallika, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” In Neuro Oncology, Vol. 17. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov206.13.Full Text Link to Item
-
-
- Teaching & Mentoring
-
Recent Courses
- PATHOL 293: Research Independent Study 2023
- BME 394: Projects in Biomedical Engineering (GE) 2022
- BME 494: Projects in Biomedical Engineering (GE) 2022
- EGR 393: Research Projects in Engineering 2022
- EGR 491: Projects in Engineering 2022
- BME 494: Projects in Biomedical Engineering (GE) 2021
- EGR 393: Research Projects in Engineering 2021
- PATHOL 293: Research Independent Study 2021
- PATHOL 793: Research Independent Study 2021
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.